IUCRO -0473  
Protocol Version Date:  
October 2 , 201 9 Page 1 A Phase II Study of Neoadjuvant FOLFIRINOX in Patients with Resectable Pancreatic 
Ductal Adenocarcinoma with Tissue Collection  
Protocol Number:  
IUCRO -0473 
Principal Investigator:  
[INVESTIGATOR_806294] , M.D.  
Indiana University School of Medicine  
Department  of Surgery  
[ADDRESS_1112968], EH 543  
Indianapolis, IN [ZIP_CODE]  
Phone: 317 -274-0339 
Email:  [EMAIL_15340]  
Study Statistician:  
Susan Perkins , Ph.D.  
Protocol Version  Date : 
10/2/2019  
Protocol [PHONE_16817] IRB Approved for re-consenting only[STUDY_ID_REMOVED]  
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1112969] OF ABBREVIATION S ................................ ................................ ................................ ................................ ..... 4 
SCHEMA ................................ ................................ ................................ ................................ .............................  6 
1. BACKGROUND & RATION ALE................................ ................................ ................................ .....................  6 
1.1 RATIONALE FOR NEOADJU VANT THERAPY IN PDAC  ................................ ................................ ................................ ..... 6 
1.2 NEOADJUVANT THERAPY I N PDAC:  (GEMCITABINE AND 5-FU +/- XRT) ................................ ................................ .........  7 
1.3 NEOADJUVANT THERAPY : (FOLFIRINOX  AND NAB -PACLITAXEL ) ................................ ................................ ...................  7 
1.4 STUDY RATIONALE  ................................ ................................ ................................ ................................ ................  8 
2. OBJECTIVES  ................................ ................................ ................................ ................................ ...............  8 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ .............  8 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ................................ ........  8 
2.3 TERTIARY OBJECTIVES ................................ ................................ ................................ ................................ ............  9 
2.4 CORRELATIVE OBJECTIVES  ................................ ................................ ................................ ................................ ...... 9 
3. OUTCOME MEASURES  ................................ ................................ ................................ ...............................  9 
3.1 PRIMAR Y OUTCOME MEASURE  ................................ ................................ ................................ ...............................  9 
3.2 SECONDARY OUTCOME MEASURES  ................................ ................................ ................................ ..........................  9 
3.3 TERTIARY OUTCOME MEASURES  ................................ ................................ ................................ .............................  9 
3.4 CORRELATIVE OUTCOME MEASURES  ................................ ................................ ................................ ........................  9 
4. ELIGIBILITY CRITERIA  ................................ ................................ ................................ ................................ . 9 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ................................ .............  9 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ...........  10 
5. STUDY DESIGN  ................................ ................................ ................................ ................................ .........  11 
6. PATIENT REGISTRATION  ................................ ................................ ................................ ...........................  11 
7. TREATMENT PLAN  ................................ ................................ ................................ ................................ .... 11 
7.1 TREATMENT DOSAGE AND ADMINISTRATION  ................................ ................................ ................................ ...........  11 
7.2 RECOMMENDED PRE-MEDICATIONS /PRECAUTIONS AND HYDRATION  ................................ ................................ ...........  13 
7.3 CONCOMITANT MEDICATIONS  ................................ ................................ ................................ ..............................  13 
8. TOXICITIES TO BE MON ITORED/DOSAGE MODIFI CATIONS  ................................ ................................ ........  [ADDRESS_1112970]-GUIDED BIOPSY PROCEDURE ................................ ................................ ................................ ................  17 
9.2 SURGICAL RESECTION  ................................ ................................ ................................ ................................ ..........  17 
10. STUDY CALENDAR  ................................ ................................ ................................ ................................ .......  19 
11. CRITERIA FOR EVALUAT ION/REMOVAL FROM STU DY ................................ ................................ ...............  [ADDRESS_1112971] OV ERALL RESPONSE  ................................ ................................ ................................ ...........  20 
11.4 METHODS OF MEASUREMENT  ................................ ................................ ................................ .........................  21 
11.5 CRITERIA FOR REMOVAL FROM TREATMENT ................................ ................................ ................................ .........  22 
12. CORRELATIVE SAMPLE C OLLECTION & ASSESSME NT, ANALYSIS  ................................ ................................  22 
12.1 TISSUE COLLECTION  ................................ ................................ ................................ ................................ .......  22 
12.2 BLOOD COLLECTION  ................................ ................................ ................................ ................................ .......  23 Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 3 12.3 NEXT GENERATION SEQUENCING METHODS (BLOOD AND TISSUE ) ................................ ................................ ..........  23 
12.3 ASSESSMENTS  ................................ ................................ ................................ ................................ ...............  24 
12.4 STUDY IDENTIFIERS  ................................ ................................ ................................ ................................ ........  24 
13. DRUG INFORMATION  ................................ ................................ ................................ ...............................  24 
13.1 OXALIPLATIN (ELOXATIN ®) ................................ ................................ ................................ ..............................  24 
13.2 IRINOTECAN (CAMPTOSAR ®) ................................ ................................ ................................ ...........................  28 
13.3 5FU................................ ................................ ................................ ................................ ............................  30 
13.4 LEUCOVORIN  ................................ ................................ ................................ ................................ ................  32 
14. STATISTICAL METHODS  ................................ ................................ ................................ ............................  33 
14.1 SAMPLE SIZE ANALYSIS AND ACCRUAL ................................ ................................ ................................ .................  33 
14.2 ANALYSIS DATASETS  ................................ ................................ ................................ ................................ .......  33 
14.3 STATISTICAL ANALYSIS PLAN  ................................ ................................ ................................ .............................  33 
14.4 CRITERIA FOR STOPPI[INVESTIGATOR_806295]  ................................ ................................ ................................ .........................  35 
15. DATA FORMS AND SUBMI SSION SCHEDULE  ................................ ................................ ..............................  35 
16. PATIENT CONSENT AND PEER JUDGMENT  ................................ ................................ ................................  35 
17. DATA AND SAFETY MONITORING  ................................ ................................ ................................ ................  36 
17.1 DATA SAFETY MONITORING COMMITTEE  ................................ ................................ ................................ ...........  36 
17.2 DATA AND SAFETY MONITORING PLAN ................................ ................................ ................................ ..............  36 
18. REPORTING ADVERSE EV ENTS  ................................ ................................ ................................ ..................  38 
18.1 DEFINITIONS OF ADVERSE EVENTS  ................................ ................................ ................................ ....................  38 
18.2 ADVERSE EVENT (AE)  REPORTING  ................................ ................................ ................................ ....................  [ADDRESS_1112972] RETENTION  ................................ ................................ ................................ ................................ .......  40 
20. REFERENCES  ................................ ................................ ................................ ................................ .............  40 
21. APPENDICES  ................................ ................................ ................................ ................................ .............  43 
APPENDIX I ................................ ................................ ................................ ................................ ................................ . 43 
APPENDIX II ................................ ................................ ................................ ................................ ................................  44 
APPENDIX III ................................ ................................ ................................ ................................ ...............................  45 
APPENDIX IV ................................ ................................ ................................ ................................ ...............................  46 
APPENDIX V ................................ ................................ ................................ ................................ ................................  48 
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1112973]  Functional Assessment of Anorexia/Cachexia 
Therapy  
FDP fibrogen degradation products  
FNA  Fine needle aspi[INVESTIGATOR_806296]  5-FU, leucovorin, irinotecan and oxaliplatin  
G-CSF Prophylactic filgrastim  
GGT  Gamma -Glutamyl Transferase  
HFSR  Hand Food Skin Reaction  
HIPAA  Health Insurance Portability and 
Accountability Act  
HUS  Hemolytic uremic syndrome  
IRB Institutional Review Board  
IV Intravenous  
ITT Intention to treat  
IUSCC  Indiana University Simon Cancer Center  
LAPC  locally advanced pancreatic cancer  
Mg Milligram  
mOS  Mean overall survival  
MRI  Magnetic resonance imaging  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1112974]  Upper limit of normal  
V Vomitting  
VOD  veno -occlusive disease  
VWF  vonWillebrand’s factor  
WOCBP  Women of childbearing potential  
 
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 6 SCHEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. BACKGROUND & RATIONALE  
Pancreatic Ductal Adenocarcinoma (PDAC) is the 4th leading cause of cancer related mortality in 
the [LOCATION_003]. Approximately 45 ,000 Americans will be diagnosed with this disease annually and the 
majority of these patients will succumb to their disease. The incidence of PDAC has been on the 
rise for unknown reas ons. Five year overall survival remains poor at 5% despi[INVESTIGATOR_806297]  (1). Fifteen to twenty percent of patients are 
diagnosed with locally resectable disease at the time of their initial presentation. There is no 
consensus  regarding  how to approach these patients, but a number of centers including Indiana 
University proceed with surgical resection first followed by [CONTACT_806313] . Adjuvant therapy includes gemcitabine or 5 -FU, based on improvement in 
disease free survival (DFS) and overall survival (OS) in patients receiving active therapy 
compared to observation alone  (2). Even in patients who undergo Whip ple surgery and adjuvant 
therapy, prognosis remains unfavorable with median overall survival ( mOS ) of less than 2 years  
(3).  As such, new approaches are needed.   
 
Long before gemcitabine was established as an option for  adjuvant therapy; it was approved in 
the metastatic setting based on clinical benefit in patients who had symptomatic advanced 
disease  (4). Over the last [ADDRESS_1112975] failed to improve outcome in patients with metastatic disease. Recently , both 
FOLFIRINOX (5 -FU, leucovorin, irinotecan and oxaliplatin) and nab -paclitaxel/gemcitabine 
were proven superior to gemcitabine alone in patients with metastatic pancreatic cancer leading 
to improvement in response rate (RR), progression free survival (PFS) and OS (5, 6).  
1.1 Rationale for neoa djuvant therapy in PDAC  
Several lines of evidence support  a neoadjuvant approach in the treatment of patients with 
pancreatic cancer  (7). This  is based on the rationale that 70-80 % of patients who undergo 
resection with curative intent still experience relapse shortly after their recovery; perhaps 
neoadjuvant therapy might spare these patients with an aggressive biology a surgery that may not 
alter the course of their disease  (8). Additionally, neoadjuvant chemotherapy provide s the 
opportunity to evaluate response to therapy “ in vivo ”, and spares patients with poor biology a 
New 
diagnosis of 
resectable 
PDAC 
surgical 
consultation 
EUS guided 
biopsy  
r 
e 
g 
i 
s 
t
r
a
t 
i
o
n 
 
2 cycles of 
FOLFIRINOX  
C/A/P CT 
scan with 
contrast 
surgical  
reevaluation  
SOC s urgery for 
patients with 
resectable 
disease  
SOC adjuvant 
therapy for 
progressive disease  
Complete 
SOC adjuvant 
therapy   (refer 
to section 7.1)  
 
Follow -up for  
progression 
and survival  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 7 large and potentially morbid operation . Prior to FOLFIRINOX (RR:  31%) and nab -
paclitaxel/gemcitabine  (RR:  23%) , the response rate to gemcitabine as a single agent was 
reported to be in a range of 6 -7 %, which was unlikely to result in a meaningful  R0 resection 
rate. Additionally, up to one -third of patients who undergo surgical resection may not recover 
well enough to undergo adjuvant therapy;  therefore, ensuring adequate treatment  in the form of 
neoadjuvant therapy theoretically  results in better delivery of therapy .  
1.2 Neoadjuvant therapy in PDAC: (Gemcitabine and 5 -FU +/ - XRT)  
In earlier studies to evaluate the safety and efficacy of combined chemoradiation  (CRT)  in the 
neoadjuvant setting, 28 patients with resectable PDAC received concurrent 5 FU based CRT  (9). 
All 28 patients completed treatment and 9 required hospi[INVESTIGATOR_806298].  Further studies evaluating this combination aimed at improving the resection rate, R0 
resection and evaluating OS  (10, 11). Studies revealed that patients who completed their 
preoperative therap y and underwent res ection experienced longer survival compared to patients 
who had surgery first  (12), or who did not undergo resection due to progression or de cline in 
functional status  (13, 14). A retrospective study using 5FU and cisplatin in combination with 
radiotherapy concluded that local control was achieved in preoperative chemoradiation with no 
significant difference in OS between the two groups  (15). Whether this is relate d to ineffective 
systemic therapy (cisplatin is ineffective in the treatment of pancreatic cancer) or local control 
(which does not correlate w ith overall survival ) is unknown.   
 
While cisplatin is not commonly used in the treatment algorithm for patients with pancreatic 
cancer, a randomized phase II study with pr eoperative gemcitabine alone versus  
gemcitabine/cisplatin concluded that the combina tion arm achieved higher R0 resection rate, 
higher node negative rate and improved DFS at one year  (16).  
1.3 Neoadjuvant therapy: (FOLFIRINOX and nab -paclitaxel)  
Based on the higher response rate to FOLFIRINOX  compared to gemcitabine, several clinical 
trials are evaluating FOLFIRINOX in a variety of settings (resectable, borderline resectable, and 
locally advance d unresectable) and in combinations with radiation therapy including intensity 
modulated radiotherapy ( IMRT ) and stereotactic body radiotherapy (SBRT). In a retrospective 
review of patients with locally advanced pancreatic cancer (LAPC), 19 received FOLFIR INOX. 
Five patients (28%) underwent R0 resection, and after a course of chemoradiotherapy, 3 more 
patients underwent R0 resection, improving the resectability rate to 44%. Another retrospective 
review using modified FOLFIRINOX in patients with non -metastat ic (Stage II, III) PDAC 
resulted in a 30% response rate, 13.7 months of mPFS and 17.8 months of mOS  (17). The 
incidence of grade 4 neutropenia, grade 3/4 diarrhea, and fatigue were 3%, 13%, and 13%, 
respect ively. Twenty -one patients with borderline resectable and LAPC were treated with 
FOLFIRINOX. Six patients (29%) required dose reductions due to toxicity. Two patients (9%) 
were unable to tolerate treatment and three patients (14%) had disease progression o n treatment. 
Seven patients (33%) underwent surgical resection following treatment with FOLFIRINOX 
alone, 2 (10%) of which were initially unresectable. Two patients underwent resection following 
FOLFIRINOX and SBRT. The R0 resection rate for patients treat ed with FOLFIRINOX + 
SBRT was 33% (55% borderline resectable, 10% unresectable). Five patients (24%) 
demonstrated a signiﬁcant pathologic response.  
 
Given the manageable toxicity of the nab -paclitaxel/gemcitabine regimen, studies evaluating its 
safety and  efficacy have been conducted and other studies are ongoing. In a small study, 16 
patients received nab -paclitaxel/gemcitabine for 3 weeks, with one week off schedule. Two Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 8 patients had progressive metastatic disease during treatment  (18). Nine patients had resection; 8 
with R0 resection. One patient had a pathologic complete response (CR) and 4 near CR. In a 
similar approach, 25 patients with localized PDAC received nab -paclitaxel/gemcitabine in a 
phase II study. Twenty patients had resection with 19/20 with R0 resection. H istologic down 
staging  was evident in 30% of patients achieving G3/4 pathologic response  (19). A phase II 
study is currently undergoing the evaluation of this combination based on risk stratif ication for 
resection incorporating IMRT  for patients with higher risk of local recurrence  (20).  
 
At Indiana University, we have been administering FOLFIRINOX for patients with good 
performance status who have borderline resectable pancreatic cancer or LAPC with the intention 
of inducing tumor response to convert their disease into a resectable disease. We have 
documented  4 cases of complete pathologic responses (pCR) and 4 cases of near (CR), which is 
very unusual in pancreatic carcinoma (unpublished data). One of the aims of the c urrent study is 
to collect pre -treatment tissues in order  to identify molecular/genetic factors that predict drug 
sensitivity.  
1.[ADDRESS_1112976] extensive surgery that may not alter the course of their disease. Incorporating the new 
combin ations of chemotherapy (FOLFIRINOX and nab -paclitaxel/gemcitabine) into the 
treatment of early stage pancreatic cancer might improve the resectability rate, DFS and OS ; 
however, only prospective clinical trials will tell. Collecting tissues to correlate be nefit from 
therapy with molecular studies and explore mechanisms of resistance will be valuable.  
 
This proposal differs from what has been previously published or investigated because it will be 
targeting only patients with resectable pancreatic cancer, and will have a tissue collection 
component which will provide a great opportunity for translational research .  Our study will also 
provide important safety information about the use of preoperative FOLFIRINOX that will 
provide a foundation for future chemotherapy/targeted therapy combinations in this setting.  
2. OBJECTIVES  
2.1 Primary Objective  
To evaluate the ra te of pathologic complete response to neoadjuvant FOLFIRINOX  in 
patients with resectable pancreatic cancer . 
2.2 Secondary Objectives  
1. To describe the adverse events associated with FOLFIRINOX when administered 
preoperatively  in patients with resectable panc reatic cancer.  
2. To estimate the fraction of patients who can successfully undergo surgery after 
neoadjuvant chemotherapy . 
3. To estimate the overall resectability rate,  rate of R0 resection,  disease  free survival 
(DFS), overall survival (OS), overall response rate ( ORR; complete respon se (CR) + 
partial response (PR)) , and disease control rate (DCR; CR + PR + stable disease 
(SD)) after administration of FOLFIRINOX in patients with resectable  pancreatic 
cancer.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 9 2.3 Tertiary Objectives  
1. Assess changes in quality of  life (global assessment and functional assessment of 
anorexia/cachexia therapy) from baseline to 4  weeks  (+/- 2 weeks) post-neoadjuvant 
chemotherapy.  
2.4 Correlative Objectives  
1. Evaluate change in CA 19 -9 and other tissue markers before and after treatment  and 
correlate with outcomes.  
2. Correlate pathologic tumor response with findings from next generation sequencing  
(NGS ).  
3. Outcome and survival data including DFS and OS will be correlated with NGS findings  
and other future research studies.  
4. Any residual tiss ue and other biologic samples (blood, serum and plasma) will be stored 
for future research  
3. OUTCOME MEASURES  
3.1 Primary Outcome Measure  
 Rate of complete pathologic response  
3.2 Secondary Outcome Measures  
 Percentage of patients to undergo surgical resection after receiving neoadjuvant 
FOLFIRINOX  
 Disease free survival and o verall survival for patients with resected pancreatic 
cancer  
3.3 Tertiary Outcome Measures  
 Patient -Generated Subjective Global Assessment (PG -SGA) score at baseline and 
4 weeks pos t neo -adjuvant therapy  
 Functional Assessment of Anorexia/Cachexia Therapy (FAACT)  at baseline and 
[ADDRESS_1112977] neo -adjuvant therapy  
3.4 Correlative Outcome Measures  
 Tissues pre (when feasible)  and post therapy will be collected and stored for 
further analy sis and future research .  
 Blood pre (when feasible) and post therapy will be collected and stored for further 
analysis and future research.  
 The planned analysis will include next generation sequencing on tissues collected 
before and after therapy. These tissues will be compared to germline evaluation 
from blood samples collected from peripheral blood.  
4. ELIGIBILITY CRITERIA  
All of the following criteria must be met in order to participate in this study:  
4.1 Inclusion  Criteria  
1. ≥ [ADDRESS_1112978] be eligible for abdominal surgery  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 10 5. Cytologically or h istologically confirmed adenocarcinoma of the pancreas  that has 
been documented to be resectable by [CONTACT_806314] a 
pancreatic surgeon  
6. Women  of childbearing potential definition  (WOCBP) must have a negative serum or 
urine pregnancy test performed within 14 days prior to initiation of F OLFIRINOX.  
Any woman (regardless of sexual orientation, having undergone a tubal ligation, or 
remaining celibate by [CONTACT_75121]) is classified as WOCBP if she meets the following 
criteria:  
a. Has not undergone a hysterectomy or bilateral oophorectomy; or  
b. Has not b een naturally postmenopausal for at least 24 consecutive months ( i.e. 
has had menses at any time in the preceding 12 consecutive months).  
7. WOCBP and men must agree to use adequate contraception prior, to study entry, for 
the duration of study participation,  and [ADDRESS_1112979] adequate organ function as defined by [CONTACT_806315]:  
a. Hemoglobin ≥ 9 g/dL (transfusions are acceptable)  
b. ANC ≥ 1.5 x 109/L 
c. Platelets ≥ 100 x 109/L 
d. Creatinine ≤ 1.[ADDRESS_1112980], or creatinine clearance ≥ 50 mL/min (estimated by 
[CONTACT_3158] -Gault or measured)  
e. Total bilirubin ≤ [ADDRESS_1112981]/ALT ≤ [ADDRESS_1112982] 3 years except for the following: adequately 
treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma  
of the skin , superficial bladder tumors (Ta, Tis & T1) , ductal carcinoma in situ 
(DCIS) of the breast and low grade prostate cancer . Any cancer  curatively treated >3 
years prior to entry  with no clinical evidence of recurrence  is permitted.  
3. Hypersensitivity to 5FU, oxaliplatin (or other platinum agents), irinotecan (or to their 
excipi[INVESTIGATOR_840]).  
4. Participation in any investigational drug study within 4 weeks preceding the start of 
study treatment. Patients are not permitted to participate in another investigational 
drug study while being treated on this protocol.  
5. Inability to receive a port or PI[INVESTIGATOR_67688].  
6. History of or suspected Gilbert’s Disease (test ing not required  if presence is not 
suspected ). 
7. Baseline peripheral neuropathy/paresthesia grade > 1. 
8. Active hepatitis B, unless patient has been on antiviral agents for at least 2 months 
(baseline testing not required).  
9. Active clinically serious infections (> grade 2).  
10. Major surgery or significant traumatic injury within [ADDRESS_1112983] John’s wort. Use of 
phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, rifampin and rifabutin is discouraged, but 
not contraindicated.  If patients require phenytoin, carbamazepi[INVESTIGATOR_806299].  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 11 12. Pregnant or lactatin g women.  
13. Psychological, familial, sociological or geographical condition potentially hampering 
compliance with the study protocol and follow -up schedule; those conditions should 
be discussed with the patient before registration in the trial.  
5. STUDY DESIG N 
This is a single arm, non -randomized , open label, prospective , phase II study for patients with 
resectable pancreatic cancer.  
6. PATIENT REGISTRATION  
All patients will be registered with the Indiana University Simon Cancer Center (IUSCC) 
Clinical Trials  Office  (CTO) . Regulatory files will be maintained by [CONTACT_806316]. 
Potential patients will be identified in the Oncology surgery clinic , endoscopy suite and 
pancreatic cancer referral program . 
 
Patients who are interested in this study at the time of their work -up and appear to be eligible for 
this trial will undergo the Informed Consent Process and be screened for eligibility . The original 
signed IRB approved Informed Consent Document and completed eligibility checklist will be 
forwarded to the CTO  designee for eligibility verification and registration in the OnCore® 
database.  
 
The expected duration of subject participation is 8-10 months (including time for surgery and 
recovery). Accrual is expected to be approxima tely 2 patients per month at Indiana University 
for a yearly accrual of approximately 24 patients and a total accrual of 48 patients. The 
approximate time to complete  study enrollment will be approximately 24 months.  
 
7. TREATMENT PLAN  
7.1 Treatment Dosage and Administration  
Patients on this trial will be treated with neoadjuvant FOLFIRINOX for 2 cycles (1 cycle = 28 
days). Patients will receive FOLFIRINOX on an outpat ient basis on days 1 and 15 of each cycle . 
Following neoadjuvant treatment, patients will undergo repeat imaging (CT or MRI) to be 
reassessed for resectability of the tumor. Further adjuvant t reatment will be determined at the 
treating physician ’s discreti on (i.e. chemoradiotherapy or adjuvant chemotherapy) . It is 
important to note that p ost-neoadjuvant  therapy is determined by [CONTACT_806317]. While this study will collect data  regarding disease 
progression and survival from the post -neoadjuvant  period , this protocol does not  dictate post-
neoadjuvant  treatment which may be done at other institutions . 
 
For patients with an R1 resection, any chemoradiotherapy will be included in t he 24 weeks of 
perioperative therapy. Chemoradiotherapy and the timing in which it will be given will be 
determined at the treating physician ’s discretion based on margin status and the patient’s 
recovery. Furthermore, patients who receive chemoradiotherap y may also receive adjuvant 
chemotherapy; however, this will be based on the treating physician ’s discretion. Recommended 
radiosensitization  will be through 5FU 200 mg/m2/Day continuous infusions M -F of each week 
or capecitabine 825 mg/m2 PO BID M -F for th e duration of radiation therapy.  Patients who Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 12 receive adjuvant therapy will receive treatment based upon treating physician ’s discretion with a 
recommended duration of therapy lasting 6 months accounting for preoperative therapy . 
 
The neoadjuvant FOLFIRINO X regimen starting doses are: oxaliplatin 85 mg/m2, followed by 
[CONTACT_13432] 400  mg/m2 given simultaneously with irinotecan 180  mg/m2, followed by 5FU 400  
mg/m2 bolus and then 2400  mg/m2 (Table 1 ). Patients require a PORT, PI[INVESTIGATOR_806300] 5FU via a continuous infusion pump. All agents should be 
administered within SOC drug administration guidelines. Appropriate dose modifications for 
each agent are described in Section 9.0. See drug monographs/package inserts for full details on 
each agent.  
 
Table 1: Chemotherapy Drugs and Modes of Administration ** 
Agent  Dose * Route  Schedule  
Oxaliplatin  85 mg/m2 in  
250 cc D5W  IV  before  irinotecan  Day 1,15 of each 28 day cycle  
Leucovorin  400 mg/m2 in 
100 cc D5W 
with irinotecan.  IV  with  irinotecan 
infusion via Y -site 
connection  Day 1, 15 of each 28 day cycle  
Irinotecan  180 mg/m2 in 
500 cc D5W 
with leucovorin.  IV with leucovorin 
infusion via Y -site 
connection  Day 1, 15 of each  28 day cycle  
5FU 400 mg/m2  IV bolus after  
irinotecan  Day 1, 15 of each 28 day cycle  
5FU 2400 mg/m2  IV after  5FU bolus  Day 1, 15 of each 28 day cycle  
*Dose should be recalculated for patients with > 10% weight change  
** Information contained in this table is intended to be used as a guideline for administering 
FOLFIRINOX chemotherapy, and modifications to this table can be made based upon institutional 
guidelines or physician discretion. These modifications will not be recorded as deviations for this 
protocol.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 13 7.2 Recommended Pre -medications/Precautions and Hydration  
Table 2 : Recommended Pre-medications, Hydration  and Prophylactic Medications * 
Agent  Dose/Precautions  Route  Schedule  
Ondansetron (or 
formulary equivalent)  [ADDRESS_1112984] patient to avoid 
exposure to cold (food, 
liquids, air) for 5 days 
following oxaliplatin  PO 30 minutes prior to 
oxaliplatin  Days 1, 15  
Dexamethasone  12 mg  PO 30 minutes prior to 
oxaliplatin  Days 1, 15  
Atropi[INVESTIGATOR_050]  0.4 mg  IV PRN for abdominal 
crampi[INVESTIGATOR_806301] 1, 15  
Promethazine  25 mg IV q6h PRN for nausea or 
vomiting  Days 1 -28 
D5W  100 cc/h  IV during treatment for 
infusions in D5W + to 
flush lines between 
medications.  Days 1, 15  
0.9% Normal Saline  2 L IV prior to/during/after 
treatment  Days  1, 15  
Loperamide (home 
instructions)  [ADDRESS_1112985] 
12 hours  PO Days 1 -28 
Pegafilgrastim  6 mg  SQ Days 1, 15  
* Information contained in this table is intended to be used as a guideline, and modifications including 
any additions or omissions to this table can be made based upon institutional guidelines or physician 
discretion. These changes will not be recorded as deviations for this protocol.  
 
7.3 Concomitant  Medications  
All pre -medications, medications for hydration, prophylactic medications and medications given 
as a result of an adverse event will be recorded in the OnCore® system.  Growth factors may be 
utilized at the investigator’s discretion.  
 
8. TOXICITIES TO BE MONITORED/DOSAGE MODIFICATIONS  
Adverse events will be recorded for all patients beginning at C1D1  (i.e. start of neoadjuvant 
treatment)  through  [ADDRESS_1112986] comple tion o f neoadjuvant therapy or progression.  
 
Each patient will be assessed for the development of any toxicity according to the Study 
Calendar  (Section 10). Toxicity will be assessed according to the NCI Common Terminology 
Criteria for Adv erse Events (CTCAE), ve rsion 4.  Dose adjustments should be made according to 
the system showing the greatest degree of toxicity.  
 
The treating physician may use his/her best clinical judgment when determining dose 
adjustments and/or holds. Dose adjustments of each agent may be made independently of dose 
modifications of the other agents (Table 3), and are based on the specific types of toxicities 
observed (Table 4).  Agents held more than 14 days for toxicity should be discontinued.  If more Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1112987] treatment delays for more than 14 days during any of the 6 cycles of 
chemotherapy  should be removed from the study.  
 
Additional detailed information on the potential adverse events and risks associated with each 
agent is included in Section 13. 
 
Table 3: Dose Levels for Toxicity  
Dose Level  Irinotecan  5FU 
Bolus / Infusion  Oxaliplatin  Leucovorin*  
Starting dose  
 (level 1)  180 mg/m2 400/2400 mg/m2 85 mg/m2 400 mg/m2 
-1 150 mg/m2 320/2000 mg/m2 65 mg/m2 400 mg/m2 
-2 120 mg/m2 240/1600 mg/m2 50 mg/m2 400 mg/m2 
*If 5FU is discontinued, leucovorin is simultaneously discontinued.  
 
 
Table  4: Dose Modifications for Toxicity  
On Day 1 or Day 15  Toxicity at any 
point during cycle  Dose Level for Subsequent 
Administration  Hematologic Toxicities  
If ANC <1.5  on the day of 
treatment , treatment will be delayed2 
for 1 week. Resume treatment when  
ANC ≥1.5 . Neutropenia  Irinotecan  5FU Oxaliplatin  
Grade 2  Maintain 
dose Maintain 
dose Maintain 
dose 
Grade 3  ↓1 dose 
level ↓1 dose 
level ↓1 dose 
level 
Grade 4  ↓2 dose 
levels  ↓2 dose 
levels  ↓2 dose 
levels  
Febrile neutropenia  ↓2 dose 
levels  ↓2 dose 
levels  ↓2 dose 
levels  
  
If platelets <75K  on the day of 
treatment , delay1 treatment for 1 
week  Resume treatment when 
platelets ≥75K . Thrombocytopenia2 Irinotecan  5FU Oxaliplatin  
≤Grade 1  Maintain 
dose Maintain 
dose Maintain 
dose 
Grade 2 -3 ↓1 dose 
level ↓1 dose 
level ↓1 dose 
level 
Grade 4  ↓2 dose 
levels  ↓2 dose 
levels  ↓2 dose 
levels  
 
Non-Hematologic Toxicities  
 
If mucositis is >Grade 2  on the day 
of treatment , treatment will be 
delayed1 for 1 week .  Resume 
treatment when mucositis <Grade 2. 
Consider use of mouth wash/rinse . Mucositis  Irinotecan  5FU Oxaliplatin  
≤Grade 2  Maintain 
dose Maintain 
dose Maintain 
dose 
Grade 3  Maintain 
dose ↓1 dose 
level Maintain 
dose 
Grade 4  Maintain 
dose ↓2 dose 
levels  Maintain 
dose 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 15 Table  4: Dose Modifications for Toxicity  
If diarrhea is >Grade 2, on the day 
of treatment, treatment will be 
delayed1 1 week. Once diarrhea is 
<Grade 2, proceed with dose 
adjusted per table.   Diarrhea  Irinotecan  5FU Oxaliplatin  
Grade 2  ↓1 dose 
level Maintain 
dose Maintain 
dose 
Grade 3  ↓1 dose 
level ↓1 dose 
level Maintain 
dose 
Grade 4  ↓2 dose 
levels  ↓2 dose 
levels  ↓1 dose 
level 
  
Electrolyte abnormalities, regardless  
of grade, do not require dose 
reductions or dose delays but should 
be corrected with aggressive  
supplementation.  Electrolyte 
Abnormalities  Irinotecan  5FU Oxaliplatin  
Any Grade  Maintain dose. Treating physician may 
reduce dose for grade 3 -4, if deemed 
appropriate  
 
Non-Hematologic Toxicities  
On Day 1 or Day 15  Toxicity at any point during 
cycle  Dose Level for Subsequent 
Administration  
If HFSR is >Grade 2, 
delay1 treatment for 1 
week .  Once HFSR is 
≤Grade 2, proceed with 
dose adjusted per table.   HFSR  Irinotecan  5FU Oxaliplatin  
≤Grade 2  Maintain 
dose Maintain 
dose Maintain dose  
Grade 3  Maintain 
dose ↓1 dose 
level Maintain dose  
Grade 4  Maintain 
dose ↓2 dose 
levels  Maintain dose  
  
If neuropathy Grade 2 
and persisting between 
treatments, or ≥Grade 
3, delay1 treatment for 1 
week .  Once neuropathy 
is ≤Grade 2 and not 
persisting, proceed with 
dose adjusted per table.   Neuropathy - motor and/or 
sensory  Irinotecan  5FU Oxaliplatin  
Grade 2 and persisting 
between treatments, OR new 
onset Grade 3 resolving to 
≤Grade 2 between treatments  Maintain 
dose Maintain 
dose ↓[ADDRESS_1112988] recurrence of Grade 3 
resolving to ≤Grade 2 
between  treatments  Maintain 
dose Maintain 
dose ↓1 further dose 
level (i.e. to 
dose level -2) 
Second recurrence of Grade 3 
resolving to ≤Grade 2 
between treatments, OR  
 Grade 3 persistent between 
treatments, OR any Grade 4  Maintain 
dose Maintain 
dose Discontinue  
  
If bilirubin is >2mg/dL, 
delay1 treatment for 1 
week . Once ≤2mg/dL, 
proceed with dose 
adjusted per table.   Increased Bilirubin3 Irinotecan  5FU Oxaliplatin  
>2 mg/dL  ↓2 dose 
levels  Maintain 
dose Maintain dose  
>3 mg/dL  Discontinue  Maintain 
dose Maintain dose  
 
 Hypersensitivity Reaction  Irinotecan  5FU Oxaliplatin  
 
Grade 1 -2  Maintain 
dose Maintain 
dose Hypersensitivity 
treatment PRN. 
May retreat at 
next treatment Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 16 Table  4: Dose Modifications for Toxicity  
day (1 or 15)  
 
≥ Grade 3  
Or if recurrent >Grade 1  Maintain 
dose Maintain 
dose Hypersensitivity 
treatment.  
Discontinue 
permanently  
  
Non-Hematologic Toxicities  
Delay1 dose of 
suspected offending 
agent(s)  for 1 week,  
until toxicity resolves to 
≤Grade 2, then resume 
treatment with dose 
adjusted per table.     Other Not -
Specified4 Irinotecan  5FU Oxaliplatin  
≥ Grade 3  ↓1 dose level (if 
suspected offending 
agent)  ↓1 dose 
level 
(if 
suspected 
offending 
agent)  ↓1 dose level  
(if suspected 
offending agent)  
Grade 4  If suspected offending 
agent, ↓1 -2 dose levels. If 
attribution not known, 
then decrease all agents. 
May discontinue at PI 
[INVESTIGATOR_9106].  If suspected 
offending 
agent, ↓1 -2 
dose levels. 
If 
attribution 
not known, 
then 
decrease all 
agents. May 
discontinue 
at PI 
[INVESTIGATOR_9106].  If suspected 
offending agent, 
↓1-2 dose 
levels. If 
attribution not 
known, then 
decrease all 
agents. May 
discontinue at PI 
[INVESTIGATOR_9106].   
 
1 Delay offending agent(s) as identified in table.  If have to delay treatment >14 days on any of the 6 
cycles of chemotherapy , discontinue agent(s). May continue non -offen ding agents per investigator 
discretion.  
 
[ADDRESS_1112989] hemolytic uremic syndrome (HUS) and/or thrombitic thromby[CONTACT_806318] (TTP), 
which is generally based on the presence of severe hemolysis, hemoglobinemia, and renal failure, draw 
the following lab  tests: creatinine, BUN, CBC, INR, PTT, fibrinogen, (fibrogen degradation products 
(FDP), antithrombin III (ATIII), vonWillebrand’s factor (VWF), antinuclear antigen (ANA), 
rheumatoid factor (RF), C3, C4, CH50, antiplatelet antibodies, platelet -associated IgG, and circulating 
immune complexes; and urinalysis. In such cases, inpatient evaluation and referral to hematology are 
recommended. Oxaliplatin should be discontinued permanently.  
 
3 If any suspi[INVESTIGATOR_806302] -occlusive disease (VOD) of liver (including hyperbilirubinemia, ascites, 
unexplained weight gain, hepatomegaly, splenomegaly, esophageal varices, or other of signs portal 
hypertension), then hold chemotherapy. If diagnosed clinically, the discontinue chemotherapy 
completely.  
 
[ADDRESS_1112990] doses f or alopecia or nausea (N) and vomiting (V) unless N&V persist for >48 hours 
despi[INVESTIGATOR_806303] -emetic support. For all other ≥ Grade 3 non -hematologic toxicities not described 
above, hold suspected agent(s) and monitor toxicity at least weekly. For Grade  3 toxicities associated 
primarily with laboratory abnormalities only (e.g. elevation of ALT, AST, lipase, Grade 3 or Grade 4 
hypophosphatemia without clinical or other evidence of pancreatitis or other hepatic dysfunction (e.g. Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 17 Table  4: Dose Modifications for Toxicity  
concomitant elevated biliru bin), study treatment may continue without interruption if this is deemed 
medically acceptable by [CONTACT_093].  
 
9. STUDY PROCEDURES  
9.[ADDRESS_1112991] -Guided Biopsy Procedure  
Pancreatic cancer is commonly staged by [CONTACT_806319]  (EUS) . This is a 
standard of care procedure which includes minimal sedation and upper endoscopy. A linear 
echoen doscope will be utilized to identify the pancr eatic mass. A fine needle aspi[INVESTIGATOR_337] (FNA) or 
core biopsy will be performed at the same time. As with sta ndard practice, biopsy  will be 
performed with on -site cytology review to confirm malignancy. All diagnostic biopsies  must be 
reviewed by [CONTACT_806320].   
 
If patients do not proceed to surgery after neoadjuvant tr eatment (may occur if the patient refuses 
surgery, is not eligible for surgery or has progression of disease), then an optional biopsy may be 
completed at the end of treatment . In these cases , a CT-guided biopsy will likely be performed. 
EUS biopsies are t ypi[INVESTIGATOR_806304] -guided  
biopsy is typi[INVESTIGATOR_806305].  
 
Biopsies may be performed prior to patient enrollment as they are standard of care for pancreatic 
cancer diagno sis. Therefore, tissue samples being stored with the Pathology Department (i.e. 
archival tissue) in lieu of fresh tissue collection may be requested after enrollment to satisfy the 
baseline tissue collection requirement of this study. Additionally, it may be difficult to 
coordinate fresh tissue collect at the time of surgical resection (see below)  or biopsy ; therefore , 
archival tissue may also be collected to satisfy the post -neoadjuvant treatment tissue collection 
requirement of this study.  
 
Additional details regarding tissue collection can be found in Section 12.1.  
9.2 Surgical Resection  
Approximately 4 weeks (+/ - 2 weeks)  after the completion of th e neoadjuvant treatment , patients 
will undergo  standard of care operative exploration and com plete extirpative surgery. Operative 
planning will be based on the original review of the patients’ initial ( i.e. pre-treatment) staging 
CT or MRI scan and the scan obtained after completion of the neoadjuvant protocol. All patients 
will undergo two modalities o f operative exploration for occult metastatic disease undetectable 
with conventional cross -sectional imaging. Prior to laparotomy, patients will undergo a formal 
two-port staging laparoscopy to exclude the presence of occult metastatic disease involving th e 
liver or peritoneal surfaces. Suspi[INVESTIGATOR_806306] a pathologic diagnosis of metastatic pancreatic adenocarcinoma. Proof of 
metastatic cancer (i.e. stage IV cancer) will exclude patients from operative resection of the 
primary pancreatic cancer. In the absence of metastatic disease detectable with staging 
laparoscopy, patients will undergo a formal laparotomy with abdominal exploration to exclude 
occult metastatic disease involving the per itoneal surfaces or liver.   
 
In the absence of occult metastatic disease, patients will undergo the planned operative procedure 
to resect the primary pancreatic adenocarcinoma completely. Based on preoperative imaging, Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 18 patients will undergo either a pancr eatoduodenectomy (PD) or distal pancreatectomy and 
splenectomy (DPS). PD will be performed for patients with head and/or neck of pancreas 
cancers. DPS will be performed for patients with body and/or tail of pancreas cancers. PD and 
DPS will be performed ac cording to standardized techniques which are employed routinely at 
Indiana University Hospi[INVESTIGATOR_307].  
 
All margins of resection will be sampled intraoperatively to ensure complete clearance. For PD, 
the neck of pancreas and bile margins will be reviewed with fr ozen section histopathologic 
analysis. For DPS, the proximal pancreatic margin (i.e. body or neck of pancreas) will be 
reviewed intraoperatively. Final margin status (R0 versus R1) of the resected specimens will be 
recorded in addition to the intraoperativ e margin status assessments.  
 
All complications within 30 days of operative resection will be recorded prospectively and 
comprehensively according to the data acquisition guidelines of the American College of 
Surgeons National Surgical Quality Improvement Program (ACS -NSQIP). All patients 
undergoing pancreatectomy at Indiana University Hospi[INVESTIGATOR_806307] -NSQIP 
database which has been modified to contain complications variables specific to pancreatic 
procedures.  
 
Patients will receive a routine , formal clinical evaluation by [CONTACT_806321] . Postoperative complications will be recorded during 
this evaluation and will be treated according to standardized practices. Patients will be eva luated 
for post -operative adjuvant chemotherapy within 4 -6 weeks from the date of the operation  as is 
routinely done after surgery . Further adjuvant treatment will be determined at the treating 
physician ’s discretion ( i.e. chemoradiotherapy or adjuvant che motherapy).  
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 19 10. STUDY CALENDAR  
1 cycle = 2 treatments over 28 
days (treatments are given every 
2 weeks)  
D1=Day 1  
D15=Day 15  Baseline1 Cycles  
1-2 Surgical 
Evaluation /EOT2 Long -term 
Follow -up9 
Post-
neoadjuvant 
tx -28 days  Day of Cycle 
(± 7 days) 4 (+/ - 2) weeks post 
neoadjuvant tx  
D1 D15 
REQUIRED ASSESSMENTS  
Medical history  X     
Height  X     
Physical examination  X X X   
BP, weight  X X X   
ECOG performance status  X X X   
Complete metabolic panel  X X X   
Calculated creatinine clearance  X X X   
Platelets, ANC & Hgb  X X X   
CA [ADDRESS_1112992], abdomen, 
pelvis  X   X5 X4 
Surgical resection  (if applicable)     X  
TREATMENT  
Neoadjuvant FOLFIRINOX   X X   
CORRELATIVE STUDIES  
Tissue collection  X6   X  
Blood collection  X6   X  
ASSESSMENTS  
PG-SGA questionnaire  X7   X8  
FAACT questionnaire  X7   X8  
 
Calendar Footnotes:  
[ADDRESS_1112993] a surgical evaluation visit  4 (+/ -2) weeks of completing or discontinuing 
neoadjuvant chemotherapy  as part of their routine care. Information collected during this visit will be 
used for the EOT visit for this study.  
[ADDRESS_1112994] of care . 
5 Repeat imaging may be performed prior to surgical resection at the treating physician ’s discretion . 
[ADDRESS_1112995] assessments should be completed within 4 (+/ -2) weeks of completing or 
discontinuing neoadjuvant chemotherapy.  
9 Follow -up for survival and disease progression will be done every 3 -6 months y ears 1 -3, every 6 months 
years 4-5, and  every 12 months thereafter . 
10 May be done by [CONTACT_806322] -person visit.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 20  
11. CRITERIA FOR EVALUATION/REMOVAL FROM STUDY  
Definitions Associated with Response Evaluation Criteria in Solid Tumors  (RECIST) version 1.  
 
Measurable disease - At baseline, tumor lesions/lymph nodes will be categorized 
measurable or non -measurable as follows:  
11.1 Measurable  
Tumor lesions  – Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:  
 [ADDRESS_1112996] scan (CT scan slice thickness no greater than 5 mm)  
 10 mm caliper measurement by [CONTACT_461] (lesions which cannot be accurately 
measured with calipers should be recorded as non -measurable)  
 [ADDRESS_1112997] X -ray 
 
Malignant lymph nodes : 
To be considered pathologically enlarged and measurable, a lymph node must be ≥ [ADDRESS_1112998] scan (CT scan slice thickness recommended to be no greater than 5 
mm). At baseline and in follow -up, only the short  axis will be measured and followed.   
11.2 New  Lesions  
There are no specific criteria for the identification  of new radiographic lesio ns; however, the 
finding of a new lesion should be unequivocal: i.e. not attributable to differences in scanning 
technique, change in imaging modality or findings thought to represent something other than tumor 
(for example, some ‘new’ bone lesions may be simply healing or flare of pre -existing lesions). 
This is particularly important when the patient’s baseline lesions show partial or complete 
response. For example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ 
cystic lesion, wh ich it is not.  
 
A lesion identified on a follow -up study in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate disease progression. An example of this is the patient 
who has visceral disease at baseline and  while on study has a CT or MRI brain ordered which 
reveals metastases. The patient’s brain metastases are considered to be evidence of PD even if 
he/she did not have brain imaging at baseline.  
 
If a new lesion is equivocal, for example because of its sma ll size, continued therapy and follow -
up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.  
11.[ADDRESS_1112999] response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for PD the smallest measurements recorded since the 
treatment sta rted). The patient’s best ove rall response assignment will depend on the findings of 
both target and non -target disease and will also take into consideration  the appearance of new 
lesions.  
 
Target 
Lesions  Non-Target 
Lesions  New Lesion?  Best Overall 
Response  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 21 CR CR No CR 
CR Non CR/  
Non PD  No PR 
CR Not evaluated  No PR 
PR Non-PD or not 
all evaluated  No PR 
SD Non-PD or not 
all evaluated  No SD 
Not all 
evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be classified as having  “symptomatic 
deterioration”.  Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
In some circumstances it may be difficult to distinguish residual disease from normal tissue.  When 
the evaluation of complete response depends on this determination, it is recommended that the 
residual lesion be investigated  (fine needle aspi[INVESTIGATOR_337]/biopsy) to confirm the complete response 
status.  
11.3.1  Missing assessments and in -evaluable designation  
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable (NE) at tha t time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not 
change the assigned time  point response.  This would be most likely to happen in the case 
of PD.  
11.3.2 Definitions of Pathological Response  
Histopathologic response after neoadjuvant therapy will be evaluated according to the 
Evan’s criteria as detailed below. T he evaluation inc ludes assessment of the amount of 
variable carcinoma remaining in conjunction with cytologic changes.  
Evans’ criteria for pathologic response 
following neoadjuvant therapy  (22) 
Grade  Tumor regression  
I <10% to no tumor cells destroyed  
II IIa: 10-50% of tumor cells destroyed  
IIb: 50-90% of tumor cells destroyed  
III >90% of tumor cells destroyed  
IIIM : sizable pools of cellular mucin  
IV No viable tumor cells  
IVM : Acellular pools of mucin  
11.[ADDRESS_1113000] be used throughout the study to measure disease.  All measurements should be Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113001] slice thickness greater than 5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. MRI is al so 
acceptable in certain situations (e.g. for body scans).  
11.4.[ADDRESS_1113002] normalize for a patient to be 
considered in complete response.  
11.5 Criteria  for removal from treatment  
A patient is conside red discontinued from the study when the decision to permanently stop 
treatment is made. Patients will be removed from the study when any of the following criteria  
apply:  
 
Unacceptable adverse events, or change in underlying condition such that the patient  can no 
longer tolerate therapy, including:  
a. Delay >14 days for administering scheduled chemotherapy due to toxicities  
b. Withdrawal of i nformed consent   
c. Investigator’s discretion  
d. Pregnancy  
 
This decision should be made by [CONTACT_2026] i nvestigator and co -investigators. The reason for 
study removal and the date the patient was removed should be documented in the electronic case 
report form (eCRF). The patient should be followed  per protocol . 
 
12. CORRELATIVE SAMPLE COLLECTION  & ASSESSMENT , ANALYSIS  
12.[ADDRESS_1113003] -neoadjuvant treatment is an important 
part of this trial. The goal of these collections is to generate findings from next generation 
sequencing (NGS) (see 1 2.2.1 for more details) to predict the pathological response versus 
progression. Additionally, future, yet undetermined, research studies will be done on any unused Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113004] of care  to establish the 
diagnosis . If there is additional tissue available  from the diagnostic biopsy samples, w e pla n on 
requesting them  either at the time of biopsy  (i.e. fresh tissue sample collection for patients who 
are already enrolled to this study)  or from the Pathology Department  (i.e. archival tissue) . For 
patients who have biopsies at  institutions outside of IUH , the PI [INVESTIGATOR_1238]/or his designee will make 
requests for any additional tissue from those respective institutions’ pathology departments.   
 
After the second cycle of neoadjuvant chemotherapy, additional tumor tissue  samples  that woul d 
otherwise be discarded , will be obtained at the time of surgical resection  or biopsy (if 
applicable) . If patients do not proceed to surgery (may occur if the patient refuses surgery , is not 
eligible for surgery or ha s progression of disease ), then an  optional biopsy  may be completed  at 
the end of neoadjuvant treatment . All research  tissue samples will be stored in the IUSCC Tissue 
Bank  or IU CTSI Specimen Storage Facility .  
 
Please refer to the study laboratory manual for complete instructions regardi ng tissue collection, 
processing, transfer and storage.  
 
12.2 Blood Collection  
Blood samples for future, yet undetermined, research studies (in addition to the blood samples  
taken as part of standard of care ) will be collected prior to treatment ( i.e. at baseline or C1D1 as 
long as completed before treatment begins) whenever possible and at the time of surgical 
evaluation ( i.e. 4 weeks [+/ -2 weeks] post neoadjuvant chemotherapy) . These  blood samples will 
be stored in the IUSCC Tissue Bank or IU CTSI Sp ecimen Storage Facility .  
 
Please refer to the study laboratory manual for complete instructions regarding tissue collection, 
processing, transfer and storage.  
 
12.3 Next Generation Sequencing Methods  (Blood and Tissue)  
Genomic sequencing of samples derive d from this trial will be performed at IU  to ascertain 
markers of response as well as to inform future studies. From the tumor biopsies, Next -
generation DNA and RNA sequencing will be performed per available technologies at the time 
of analysis. One such m ethod that may be used is described below.  
 
For each sample, DNA & RNA will be extracted from tumor biopsies along with DNA from 
matched whole blood. Briefly, 40ng of DNA will undergo a highly multiplexed PCR reaction to 
amplify all exons of 409 genes known to be mutated in cancer (Sanger Gene Census) using the 
Ion Ampliseq Comprehensive Cancer Panel. This panel is specifically designed for amplification 
of both formalin -fixed paraffin embedded samples as well fresh/frozen tissue. Subsequent to 
amplific ation, libraries will be sequenced on an Ion Proton Sequencer using 200bp fragment 
chemistry and an Ion Proton I chip. It is estimated that each sample will have 1500 -2000X 
average coverage of each cancer gene, enabling low allele frequency somatic mutatio n detection. 
Each sequencing run will be evaluated for technical quality control metrics. For bioinformatics 
analysis, reads will be mapped to the human genome using the TMAP algorithm. After mappi[INVESTIGATOR_007] , 
somatic variants will be called (point mutations, indel s, and copy number variation), using the Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 24 Ion Reporter pi[INVESTIGATOR_19189] (Life Technologies). Annotation of identified variants will be performed 
by [CONTACT_12783] -referencing the following databases: NIH dbSNP, [ADDRESS_1113005], COSMIC 
(Catalog of Somatic Mutations in C ancer), and TCGA (The Cancer Genome Atlas). 
Identification of cancer driver variants, association with therapeutic interventions, and mutational 
network analyses will be performed using Ingenuity Variant Analysis (Ingenuity Systems). All 
data and analyses will be stored on the HIPPA -compliant Indiana University Scholarly Data 
Archive.  
 
For expression analysis 10ng of RNA (extracted as described above) will undergo library 
preparation using the Ion Ampliseq Transcriptome Human Gene Expression Kit. This will allow 
for accurate quantitative expression of ~20,[ADDRESS_1113006] express ion files.  
12.3 Assessments  
Patients will be given the following questionnaires to complete via paper or in electronic format 
(online , email, or on a tablet) prior to treatment ( i.e. at baseline or C1D1 as long as completed 
before treatment begins) and at the time of surgical evaluation ( i.e. 4 weeks [+/ -2 weeks] post 
neoadjuvant chemotherapy) . 
12.3.1 Scored Patient -Generated Subjective Global Assessment (PG -SGA)  
The Scored Patient -Generated Subjective Global Assessment (PG -SGA) includes the 
four patient -generated historical components (Weight History, Food Intake, Symptoms 
and Activities and Function), the professional part (Diagnosis, Age, Metabolic stress, 
and Physical Exam), the Global Assessment (A = well nourished, B = moderately 
malnourished or suspec ted malnutrition, C = severely malnourished), the total 
numerical score, and nutritional triage recommendations. Subsequently, the Scored PG -
SGA allows for triaging of specific nutrition interventions, as well as facilitating 
quantitative outcomes data col lection.23 
 
12.3.2 Functional Assessment of Anorexia/Cachexia Therapy (FAACT)  
The Functional Assessment of Anorexia/Cachexia Therapy (FAACT)  is a comprehensive 
questionnaire  used for patient self -report of anorexia and appetite assessment  that 
contains gen eral core questions of the Functional Assessment of Chronic Illness 
Treatment (FACIT)  plus questions about nutritional issues including appetite.[ADDRESS_1113007] ownership of any tissue or blood samples that are stored for future research. 
Distribution of samples will be at PI [INVESTIGATOR_9106]; however, samples will not be sold. Any samples 
that are distributed to researchers outside of the study team, w ill anonymized and only identified 
by a coded number.   
13. DRUG INFORMATION  
13.1 Oxaliplatin (Eloxatin®)  
Oxaliplatin is a platinum -based drug that forms crosslinks of guanine that inhibit DNA 
replication and transcription. Cytotoxicity is cell -cycle nonspecific. It is indicated for the 
treatment of metastatic CRC in combination with 5FU and leucovorin.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 25 Supply and Supplier  
Oxaliplatin as Eloxatin® is available from [COMPANY_011] -Aventis in powder form in two strengths ( 50 
mg or 100 mg), and as a sterile, preservative -free, aqueous solution at a concentration of 5 mg/ml 
in 3 sizes: [ADDRESS_1113008] be diluted prior to intravenous infusion. See Full 
Prescribing Information at:  http://products.sanofi -aventis.us/eloxatin/eloxatin.html  for complete 
information. C ommercially available supplies of either Eloxatin® or generic oxaliplatin will be 
used for this study.   
Preparation, Storage and Stability  
The appropriate dose of oxaliplatin (see Section  7.1) should be reconstituted, diluted and stored 
according to the package insert provided by [CONTACT_806323]. Reconstitution or final dilution must never be performed with a 
sodium chloride solution or other chloride containing solutions.  
Premedication  
Patients should be prescribed medications to prevent and treat nausea and vomiting as per 
institutional guidelines .  
Dosage and Administration  
See Section  7.1.   
Handling and D isposal  
As with other potentially  toxic anticancer agents, care should be exercised in the handling and 
preparation of infusion solutions prepared from oxaliplatin. The use of gloves is recommended. If 
a solution of oxaliplatin contacts the skin, wash the skin immediately and thoroughly w ith soap 
and water. If oxaliplatin contacts the mucous membranes, flush thoroughly with water. Procedures 
for the handling and disposal of anticancer drugs should be considered.   
Adverse Events  
Incidence rates of adverse events associated with oxaliplati n are provided in the products’ Full 
Prescribing Information ( http://products.sanofi -aventis.us/eloxatin/eloxatin.html ). Some of the 
adverse events expected with oxaliplatin treatment  are listed below.  
 
More than 1100 patients with stage II or III colon cancer and > [ADDRESS_1113009] been treated in clinical studies with Eloxatin®.  The most common adverse reactions in 
these trials (incidence ≥ 40% of patients) were p eripheral sensory neuropathy, neutropenia, 
thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, 
emesis, fatigue and stomatitis.  
 
Hematologic : When oxaliplatin was used in combination with 5FU and leucovorin in previously 
untreated advanced CRC, the percent of patients who experienced hematological toxicities (all 
grades/grade ≥3) were: anemia (27%/3%)  leukopenia (85%/20%), neutropenia (81%/53 %), 
infection with grade ≥3 neutropenia (8%), febrile neutropenia (4%) and thrombocytopenia 
(71%/5%).  Epi[INVESTIGATOR_806308] 10% of patients, versus 1% in those receiving irinotecan plus 
5FU and leucovorin.  
 Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 26 Gastrointestinal : When oxaliplatin was used in c ombination with 5FU and leucovorin in 
previously untreated advanced CRC, the percent of patients who experienced gastrointestinal 
toxicities (all grades/grade ≥3) were: nausea (71%/6%), diarrhea (56%/12%), vomiting 
(41%/4%), and stomatitis (38%/0%).  Preme dication with antiemetics, including 5 -HT3 blockers, 
is recommended. Diarrhea and mucositis may be exacerbated by [CONTACT_806324] 
5FU/leucovorin, and should be managed with appropriate supportive care. Since cold 
temperature can exacerbate acute neurological symptoms, ice (mucositis  prophylaxis) should be 
avoided during the infusion of oxaliplatin.  
 
Dermatologic:  When oxaliplatin was used in combination with 5FU and leucovorin in previously 
untreated advanced CRC, the percent of patients who experienced hand -foot syndrome was 7%.  
 
Intravenous Site Reactions : Extravasation, in some cases including necrosis, has been reported. 
Injection site reaction, including redness, swelling, and pain, has been reported.  
 
Anticoagulation and Hemorrhage : There have been reports while on study and fro m post -
marketing surveillance of prolonged prothrombin time and INR occasionally associated with 
hemorrhage in patients who received oxaliplatin plus 5FU/leucovorin while on anticoagulants. 
Patients receiving oxaliplatin plus 5FU/leucovorin and requiring o ral anticoagulants may require 
closer monitoring.  
Renal:  About 5 -10% of patients in all clinical trial group s in the oxaliplatin trials in CRC had some 
degree of elevation of serum creatinine.  
Thromboembolism : When oxaliplatin was used in combination with 5FU and leucovorin in 
previously untreated advanced CRC, the percent of patients who experienced thromboembolic 
events was 6%.  
 
The following toxicities are noted with particular Warnings and Precautions in the prescribing 
information for Eloxatin®:  
 
1. Neuro pathy : Oxaliplatin is associated with two types of neuropathy:  
a. An acute, reversible, primarily peripheral, sensory neuropathy that is of early 
onset, occurring within hours or one to two days of dosing, that resolves within [ADDRESS_1113010] also been observed. The acute, reversible pattern 
of sensory neuropathy was observed in about 56% of study patients who received 
oxaliplatin with 5FU/leucovorin. In any  individual cycle acute neurotoxicity was 
observed in approximately 30% of patients. In adjuvant patients the median cycle of 
onset  for grade 3 peripheral sensory neuropathy was 9 in the previously treated patients 
the median number of cycles administered on the oxaliplatin with 5FU/leucovorin 
combination arm was 6.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 27 An acute syndrome of pharyngolaryngeal dysesthesia seen in 1 –2% (grade 3/4) of 
patients previously untreated for advanced colorectal cancer, and the previously treated 
patients, is characterized  by [CONTACT_435405], without any 
laryngospasm or bronchospasm (no stridor or wheezing). Ice (mucositis prophylaxis) 
should be avoided during the infusion of oxaliplatin because cold temperature can 
exacerbate acute neurologica l symptoms.  
b. A persistent (>14 days), primarily peripheral, sensory neuropathy that is usually 
characterized by [CONTACT_227790], dysesthesias, hypoesthesias, but may also include 
deficits in proprioception that can interfere with daily activities ( e.g. writing , 
buttoning, swallowing, and difficulty walking from impaired proprioception).  
These forms of neuropathy occurred in 48% of the study patients receiving oxaliplatin 
with 5FU/leucovorin. Persistent neuropathy can occur without any prior acute 
neuropathy eve nt. The majority of the patients (80%) who developed grade 3 persistent 
neuropathy progressed from prior Grade 1 or 2 events. These symptoms may improve 
in some patients upon discontinuation of oxaliplatin.  
Overall, neuropathy was reported in patients prev iously untreated for advanced 
colorectal cancer in 82% (all grades) and 19% (grade 3/4), and in the previously treated 
patients in 74% (all grades) and 7% (grade 3/4) events. Information regarding 
reversibility of neuropathy was not available from the tria l for patients who had not 
been previously treated for colorectal cancer.  
The following warnings and precautions are less common but serious adverse events associated 
with oxaliplatin:  
 
2. Anaphylactic Reactions : These have been reported, and may occur within minutes of 
oxaliplatin  administration. Epi[INVESTIGATOR_238], corticosteroids, and antihistamines have been 
employed to alleviate symptoms. Grade 3/4 hypersensitivity, including 
anaphylactic/anaphylactoid reactions, to  oxaliplatin has been observed in 2 –3% of colon 
cancer patients. These allergic reactions which can be fatal, can occur within minutes of 
administration and at any cycle, and were similar in nature and severity to those reported 
with other platinum -contain ing compounds, such as rash, urticaria, erythema, pruritus, and, 
rarely, bronchospasm and hypotension. The symptoms associated with hypersensitivity 
reactions reported in the previously untreated patients were urticaria, pruritus, flushing of the 
face, dia rrhea associated with oxaliplatin infusion, shortness of breath, bronchospasm, 
diaphoresis, chest pains, hypotension, disorientation and syncope. These reactions are usually 
managed with standard epi[INVESTIGATOR_238], corticosteroid, antihistamine therapy, and may require 
discontinuation of therapy. Drug -related deaths associated with platinum compounds from 
anaphylaxis have been reported.  
3. Pulmonary Toxicity : Oxaliplatin has been associated with pulmonary fibrosis (<1% of study 
patients), which may be fatal. The com bined incidence of cough and dyspnea was 7.4% (any 
grade) and <1% (grade 3) with no grade 4 events in the oxaliplatin plus infusional 
5FU/leucovorin arm compared to 4.5% (any grade) and no grade 3 and 0.1% grade 4 events in 
the infusional 5FU/leucovorin al one arm in adjuvant colon cancer patients. In this study, one 
patient died from eosinophilic pneumonia in the oxaliplatin combination arm. The combined 
incidence of cough, dyspnea and hypoxia was 43% (any grade) and 7% (grade 3 and 4) in the 
oxaliplatin pl us 5FU/leucovorin arm compared to 32% (any grade) and 5% (grade 3 and 4) in Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 28 the irinotecan plus 5FU/leucovorin arm of unknown duration for patients with previously 
untreated colorectal cancer. In case of unexplained respi[INVESTIGATOR_397685] -
product ive cough, dyspnea, crackles, or radiological pulmonary infiltrates, oxaliplatin should 
be discontinued until further pulmonary investigation excludes interstitial lung disease or 
pulmonary fibrosis.  
4. Hepatotoxicity : Hepatotoxicity appears to be related to oxaliplatin combination therapy. When 
oxaliplatin was used in combination with 5FU and leucovorin in previously untreated advanced 
CRC, the percent of patients who experienced hepatotoxicity (all grades/grade ≥3) were ALT 
elevation (6%/1%), AST elevation ( 17%/1%), alkaline phosphatase elevation (16%/0%), and 
total bilirubin elevation (6%/1%).   In the study of oxaliplatin and 5FU/leucovorin versus 
5FU/leucovorin alone in patients with colon cancer receiving chemotherapy as adjuvant 
treatment,  hepatotoxicit y was observed more frequently in the oxaliplatin arm, as evidenced 
by [CONTACT_806325] (57% vs. 34%) and alkaline phosphatase (42% vs. 20%). The 
incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies 
include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal 
fibrosis, and veno -occlusive lesions. Hepatic vascular disorders should be considered, and if 
appropriate, should be investigated in case of abnormal liver function test r esults or portal 
hypertension, which cannot be explained by [CONTACT_397792].  
Drug Interactions  
No specific cytochrome P -450-based drug interaction studies have been conducted. No 
pharmcokinetic  interaction between 85 mg/m2 oxaliplatin and 5FU/leucovorin h as been observed 
in patients treated every 2 weeks. Increases of 5FU plasma concentrations by [CONTACT_3450] 20% 
have been observed with doses of 130 mg/m2 oxaliplatin dosed every 3 weeks. Because 
platinum -containing species are eliminated primarily through  the kidney, clearance of these 
products may be decreased by [CONTACT_3252] -administration of potentially nephrotoxic compounds; 
although, this has not been specifically studied    
 13.2 Irinotecan (Camptosar®)  
Irinotecan hydrochloride is a semisynthetic derivative of  camptothecin and is an antineoplastic 
agent of the topoisomerase I in hibitor class.  It is a prodrug of the active metabolite, SN38, that 
produces DNA breakage and cell death. (21). It is indicated for the treatment of metastatic CRC 
in combination with 5FU and leucovorin.  
Supply and Supplier  
Irinotecan as Camptosar® is available fr om [COMPANY_007] in single -dose amber glass vials containing 40 
mg/2 mL or 100mg/5mL, and must be diluted prior to intravenous infusion.  See Full Prescribing 
Information at: https:/ /www.pfizeroncology.com/sites/pop/PDFs/uspi_camptosar.pdf  for 
complete information. Commercially available supplies of either Camptosar® or generic 
irinotecan will be used for this study.   
Preparation, Storage and Stability  
The appropriate dose of irinote can (see Section  7.1) should be reconstituted, diluted and stored 
according to the package insert provided by [CONTACT_806323].  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 29 Premedication  
Patients should be prescribed medications to prevent and treat n ausea and vomiting as per 
institutional guidelines .      
Dosage an d Administration  
See Section  7.1. 
Handling and Disposal  
To minimize the risk of dermal exposure, always wear impervious gloves when handling vials 
containing irinotecan. This includes all ha ndling activities in clinical settings, pharmacies, 
storerooms, and home healthcare settings, including during unpacking and inspection, transport 
within a facility, and dose preparation and administration.  If a solution of irinotecan contacts the 
skin, w ash the skin immediately and thoroughly with soap and water.  If irinotecan contacts the 
mucous membranes, flush thoroughly with water.  Procedures for proper handling and disposal 
of anti -cancer drugs should be considered.  
Adverse Events  
Incidence rates  of adverse events associated with irinotecan are provided in the products’ Full 
Prescribing Information ( https://www.pfizeroncology.com/sites/pop/PDFs/uspi_camptosar.pdf ). 
Some of the adverse events expected with irinotecan treatment are listed below.  
 
Nausea, vomiting and diarrhea are common adverse events following treatment with irinotecan, 
and can be severe.  When observed, nausea and vomiting usually occur during or shortly after 
infusion of irinotecan.  
 
Diarrhea : Irinotecan can induce both early and late forms of diarrhea that appear to be mediated 
by [CONTACT_129427]. Early diarrhea (occurring during or shortly after infusion of irinotecan) 
is cholinergic in nat ure. It is usually transient and only infrequently is severe. It may be 
accompanied by [CONTACT_59598], increased salivation, miosis, lacrimation, 
diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal crampi[INVESTIGATOR_007]. Ea rly 
diarrhea and other cholinergic symptoms may be prevented or ameliorated by [CONTACT_329639][INVESTIGATOR_050].  Late diarrhea (generally occurring more than 24 hours after administration of 
irinotecan) can be life threatening since it may be prolonged and may lead to dehydration, 
electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide.  
Patients with diarrhea should be carefully monitored, should be given fluid and electrolyte 
replacement if they become dehydrated, and should be given antibiotic support if they develop 
ileus, fever, or severe neutropenia.  
 
Hepatic :  In the clinical studies evaluating the weekly dosage schedule, NCI grade 3 or 4 liver 
enzyme abnormalities were observed in fewer than 10% of patients.  These even ts typi[INVESTIGATOR_435387].   
 
Hematologic : Irinotecan commonly causes neutropenia, leucopenia (including lymphocytopenia) 
and anemia.  Deaths due to sepsis following severe neutropenia have been reported in patients 
recei ving irinotecan.    Individuals who are homozygous for the UGT1A1*28 allele 
(approximately 10% of North American population) are at increased risk for neutropenia 
following initiation of irinotecan treatment.  Serious thrombocytopenia is uncommon. SN -38, the 
active metabolite of irinotecan, is predominantly converted to its glucuronide metabolite, which Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 30 is essentially inactive, and subsequently eliminated in bile and feces. Based on this, patients with 
known defective UGT1A1 (Gilbert’s syndrome) will be exc luded from this trial.   
 
Body as a Whole:  Asthenia, fever, and abdom inal pain are generally the most common events of 
this type.  
 
Hypersensitivity :  Hypersensitivity reactions including severe anaphylactic or anaphylactoid 
reactions have been observed.  
 
Colitis/Ileus:   Cases of colitis complicated by [CONTACT_55781], bleeding, ileus, and infections have 
been observed.  Patients experiencing ileus should receive prompt antibiotic support.  
 
Renal Impairment/Renal Failure :  Rare cases of renal impairment and acute  renal failure have 
been identified, usually in patients who became volume depleted from severe vomiting and/or 
diarrhea.   
 
Thromboembolism:  Thromboembolic events have been observed in patients receiving irinotecan; 
the specific cause of these events has not been determined.  
  
Respi[INVESTIGATOR_696] : In clinical studies, ≥Grade 3 dyspnea was reported in 4% of patients.  Of note, over 
half of these patients had lung metastases.    Interstitial pulmonary disease, which can be fatal, is 
uncommon.  Risk factors include p re-existing lung disease, use of pneumotoxic drugs, radiation 
therapy, and colony stimulating factors.   
Drug Interactions  
Exposure to irinotecan and its active metabolite SN -[ADDRESS_1113011]. John’s Wort.  
Strong inhibitors of CYP3A4 enzymes such as the anti -fungal ketoconazole and the HIV anti -
retrovirals ( e.g. atazanav ir), have increased exposure to irinotecan and SN -38 and should be 
avoided in patients receiving irinotecan.  See https://www.pfizeroncology.com/sites/pop/ 
PDFs/uspi_campto sar.pdf  for further information. See Section 7.3 for further inform ation on 
prohibited concomitant drugs, and drugs to be used with caution.   
13.3 5FU 
5FU is an antineoplastic anti -metabolite that interfers with the synthesis of DNA and to a lesser 
extent  RNA by [CONTACT_806326].  It is 
indicated for the treatment of metastatic CRC.   
Supply and Supplier  
The following information was taken from the prescribing information for Teva [LOCATION_003]’s Adrucil® 
(5FU).  Additional details  may be found at : 
http://www.tevausa.com/assets/base/products/pi/Adrucil_PI.pdf .   
 
Each 10 mL contains 500 mg of FU (50 mg/mL) and sodium hydroxide to adjust pH to 
approximately 9.2.  Commercially available supplies of either Adrucil® or another generic 5FU 
will be used for this study  based on cost and availability .   Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 31 Preparation, Storage and Stability  
The appropriate dose of 5FU (see Section  7.1) should  be reconstituted, diluted and stored 
according to the package insert provided by [CONTACT_806323].  
 
Premedication/Hydration  
Patients should receive premedication and hydration as described earlier.  
Dosage  and Administration  
See Section  7.1. 
Handling and Disposal  
To minimize the risk of dermal exposure, always wear impervious gloves when handling vials 
containing 5FU. This includes all handling activities in clinical settings, pharmacies, storerooms, 
and ho me healthcare settings, including during unpacking and inspection, transport within a 
facility, and dose preparation and administration.  If a solution of 5FU contacts the skin, wash 
the skin immediately and thoroughly with soap and water.  Procedures for proper handling and 
disposal of anti -cancer drugs should be considered.  
Adverse Events  
The most common toxicities seen with 5FU therapy include stomatitis, esophagopharyngitis 
(which may result in sloughing and ulceration), diarrhea, anorexia, nausea and  vomiting.  
Neutropenia commonly follows treatment with white count nadir observed between days 9 and 
14 following therapy.  Mild alopecia has been reported, though is usually not complete.  
Dermatitis, in the form of a pruritic maculopapular rash that usu al appears on the extremities and 
(less frequently) trunk, is generally reversible and responsive to symptomatic treatment.  This 
dermatitis may be increased with sun exposure.  
  
Other less common adverse reactions are:  
Hematologic : pancytopenia, thromboc ytopenia, agranulocytosis, anemia.  
 
Cardiovascular : myocardial ischemia, angina.  
 
Gastrointestinal : gastrointestinal ulceration and bleeding.  
 
Allergic Reactions : anaphylaxis and generalized allergic reactions.  
 
Neurologic : acute cerebellar syndrome (which  may persist following discontinuance of 
treatment), nystagmus, headache.  
 
Dermatologic : dry skin; fissuring; photosensitivity, as manifested by [CONTACT_806327][INVESTIGATOR_16575]; vein pi[INVESTIGATOR_371]; palmar -plantar erythrodysesthesia syndrome, as 
manifested by [CONTACT_177428], erythema and swelling.  
 
Ophthalmic : lacrimal duct stenosis, visual changes, lacrimation, photophobia.  
 
Psychiatric : disorientation, confusion, euphoria.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 32  
Miscellaneous : thrombophlebitis, epi [INVESTIGATOR_3940], nail changes (including loss of nails)  
 13.4 Leucovorin  
Leucovorin, also known as folinic acid or citrovorum factor is a chemically reduced derivative of 
folic acid.  Leucovorin is readily converted to another rduced folate, 5,10-
methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyuridy lic acid to 
thymidylate synthase, thereby [CONTACT_806328].   It is used to enchance 
the effects of fluoropyrimdines such as 5FU.   
Supply and Sup plier 
The following information was taken from the prescribing information for Sagent 
Pharmaceutical’s leucovorin calcium.  
 
Leucovorin calcium is commercially available as a sterile, single -use vial containing either 
100mg or 350mg each. Commercially avail able supplies of generic leucovorin calcium will be 
obtained from Sagent or another manufacturer and used for this study.  
Preparation, Storage and Stability  
The appropriate dose of leucovorin (see Section  7.1) should be reconstituted and diluted and 
store d according to the package insert provided by [CONTACT_806323].  
Dosage and Administration  
See Section  7.1. 
Adverse Events Associated with Leucovorin  
Leucovorin should not be used for pernicious anemia and o ther megalobastic anemias secondary 
to the lack of vitamin B12.  A hematologic remission may occur while neurologic manifestations 
continue to progress.   
 
Leucovorin enhances the toxicity of 5FU.  When these drugs are administered concurrently in 
the trea tment of advanced colorectal cancer, as they are in this study, gastrointestinal toxicities 
(particularly stomatitis and diarrhea) are observed more commonly and may be more severe and 
of prolonged duration.  Seizures and/or syncope have been reported rare ly in cancer patients 
receiving leucovorin, usually in combination with fluoropyrimidine administratiaon, and most 
commonly in those with CNS metastases or other predisposing factors, however, a causal 
relationship has not been established.  
 
Allergic sens itization, including anaphylactoid reactions and urticaria, has been reported 
following administration of leucovorin.   
Drug Interactions  
Folic acid in large amounts may counteract the antiepi[INVESTIGATOR_806309], phenytoin 
and primidone, and increase the frequency of seizures in susceptible pediatric patients.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 33 14. STATISTICAL METHODS  
14.1 Sample size analysis and accrual  
The pathological  complete response with traditional chemotherapy in pancreatic cancer is very 
low (no reported complete response in neoadjuvant studies). We aim to evaluate the  complete 
response rate  and the correlation with outcome . So we assume the p athological  complete 
response in traditional chemotherapy to be 1%. We expect that the pathological complete 
response after 2  cycles of FOLFIRINOX  therapy is about 10%. We plan to enroll  48 patients 
over a 24 months period. Assuming 90%  of patients are evaluable for response , we will have [ADDRESS_1113012] 82% power detect a significant difference from the traditional chemotherapy with a 5% 
Type I error rate using a two si ded one -sample test for proportion.  
14.[ADDRESS_1113013] -baseline 
assessment or die before any evaluation.   
Not Evaluable  for 
Efficacy  This will comprise of patients who do not complete 2 out 
of 4 treatments unless it is related to profound to xicity 
leading to treatment discontinuation.  
Safety  This will comprise all patients that contribute data to the 
safety analysis. This population should be specifically 
defined in the protocol.  
 
14.3 Statistical analysis plan  
Primary  Outcome : 
 Pathologic complete response: the proportion of the 48 patients having a pathologic 
complete response with a 95% confidence interval (using normal approximation) will 
be calculated.   
 
Secondary Outcomes : 
 Safety:  Adverse events of grades 3 , 4, 5 by [CONTACT_12397] v4.3 criteria for each category 
listed in section 2.1.6 will be summarized. The proportion of patients with each 
category of AE will be calculated with a 95% confidence interval. After the 
enrollment of the first 20 patients, we will evaluate the rat e of surgical resection. If >6 
patients are not able to proceed with surgery due to excessive toxicity or progression 
(not including occult metastatic peritoneal disease that was found during surgery and 
not on imaging) the study will discontinue due to un acceptable toxicity.  
 Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 34  Ability of patients to undergo surgical resection after receiving neoadjuvant 
FOLFIRINOX : the proportion of patients who are able to go through surgery among 
those who have resectable tumor will be calculated accompanied with a 95% 
confidence interval.   
 
 Rate of resectability  will be evaluated by [CONTACT_806329] (R0 vs R1) 
resection. A 95% confidence interval will be constructed for the rate.  
 
 Disease free survival (DFS): DFS is defined as time from registration to evidence of 
tumor recurrence (including clinical deterioration related to the underlying pancreatic 
cancer, as assessed by [CONTACT_093]) or death from any cause. Kaplan -Meier cur ve 
for DFS will be plotted. Median DFS time will be calculated accompanied with a 
95% confidence interval.  
 
 Overall survival : time from registration to death for 48 patients with right censoring 
will be analyzed using Kaplan -Meier estimate. Median survival  time will be obtained 
accompanied with a 95% confidence interval.  
 
 Objective response rate:  proportion of patients with complete responses (CR) or 
partial responses (PR) after 4 cycles of FOLFIRINOX  treatment will be constructed 
with a 95% confidence inte rval. 
 
 Disease control rate:  Proportion of patients with complete responses (CR), partial 
responses (PR), or stable disease (SD) after 4 cycles of F OLFIRINOX  treatment will 
be obtained with a 95% confidence interval.  
 
Tertiary Outcomes : 
 Quality of life measures (from PG -SGA and FAACT) will be summarized with 
descriptive statistics and compared between baseline and [ADDRESS_1113014] neo -adjuvant 
therapy with paired t -tests.  
 
Correlative Outcomes : 
 Change of biomarkers (in cluding Ca19 -9 and other tissue m arkers)  from baseline to 
after [ADDRESS_1113015] the 
change. We will correlate the change of Ca19 -9 with patients’ pathologic complete 
response  using logistic regress ion model or  overall survival using  Cox proportional 
hazards model as appropriate. Biomarker s will also be correlated with P FS and other 
response outcomes similarly.  
 
 Differential expression will be perf ormed in R using DESeq2. These files will be 
downloaded and uploaded to Partek Genomics Suite  v6.[ADDRESS_1113016] Analysis.  CIBERSORT analysis 
to identify the immune cell make up based on g ene expression will also be performed.  
Selected differentially expressed markers will be correl ated with outcomes as 
describe above.   Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 35 14.4 Criteria for stoppi[INVESTIGATOR_806310] d if 25-30% o f patients are unable to complete  surgery  due to 
toxicity . Analysis will be conducted after the first 20 patients are enrolled onto the study . If >6 
patients are not able to proceed with surgery due to excessive toxicity the study will discontinue 
due to unacceptable toxicity.  
 
15. DATA FORMS AND SUBMISSION SCHEDULE  
This study will utilize electronic Case  Report Form completion in the OnCore® database . A 
calendar of events and required forms are available in OnCore®. The OnCore® database  is a 
comprehensive database used by [CONTACT_806330] ( CTO) and supported by [CONTACT_806331] (CTSI) .   
 
Access to data through OnCore® is restricted by [CONTACT_113298].  Once logged 
into the OnCore® system  with a user ID and password, OnCore® defines roles for each user 
which limits access to appropriate data.  New u sername  [CONTACT_2383] s can be obtained by [CONTACT_806332] : https://redcap.uits.iu.edu/surveys/?s=sYN36a9U5c .  For further questions 
regarding your oncore account you can contact [CONTACT_806333]: [EMAIL_15341] .   
 
All source documents are to remain in the patient’s clinic file.  All documents should be kept 
according to applicable federal guidelines.  Clinical  trial data in OnCore® are periodically 
monitored by [CONTACT_806334].   
 
Generally, clinical and correlative data will b e electronically captured in OnC ore®. If procedures 
on the study calendar are performed for standard of care, at minimum, that data will be captured 
in the medical record . Select standard of care d ata will also be captured in OnC ore®, according to 
study -specific objectives. Please see the OnC ore® data collection guidelines for further details.  
Tissues will be stored in the IUSCC and data will be kept in OnCore® in a BSM . 
 
16. PATIENT CONSENT AND PEER JUDGMENT  
The protocol and informed consent form for this study mu st be approved in writing by [CONTACT_115480] (IRB) pri or to any patient being registered on this study.   
 
Changes to the protocol, as well as a change of principal investigator, must also be approved by 
[CONTACT_164950].  Records of the Institutional Review Board review and approval of all documents 
pertaining to t his study must be kept on file by [CONTACT_093] (housed in the Clinical Trials  
Office) and are subject to inspection at any time during the study.  Periodic status reports must be 
submitted to the Institutional Review Board at least yearly, as well as n otification of completion 
of the study and a final report within 3 months of study completion or termination.   
 
The study will be  conducted in compliance with ICH guidelines and with all applicable federal 
(including 21 CFR parts 56 & 50), state or local laws.  
 Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 36 17. DATA AND SAFETY MONITORING  
17.1 Data Safety Monitoring Committee  
The Data Safety  Monitoring Committee ( DSMC) of the Indiana University Simon Cancer Center  
(IUSCC ) is responsible for patient safety and privacy protection, compliance with required 
reporting, and study integrity for all trials conducted at IUSCC. Members are subject matter 
experts from multiple  disciplines including medical oncology, pediatrics, biost atistics, behavioral 
oncology, radiation oncology, urology, surgery, gynecologic oncology, data and project 
management and research administration  who are appointed by [CONTACT_806335] . The DSMC 
will provide independent oversight of the clinical trial so tha t study integrity is assured. 
However, the DSMC is not serving as a Data and Safety Monitoring Board (DSMB) for this  
study.  The DSMC will meet per the currently approved DSMP , led by [CONTACT_806336], and will review all adverse events, moni toring and auditing reports, unanticipated 
problems and study non -compliance events that requir e expedited reporting .  Meeting  minutes 
will be  maintained  in the IUSCC Clinical Trials  Office ( CTO ). Specifically the DSMC has the 
following responsibilities:  
 Assessment of the adequacy of trial -specific Data Monitoring and Safety Plan (DSMP) of 
studies that are not subject to external monitoring, including investigator initiated studies, 
and establish risk based monitoring determination of trial specific DSMB.  
 Review safety data for investigator initiated trials including all adverse events, unanticipated 
problems and study non -compliance events requiring expedited reporting . 
 Conduct routine study monitoring and auditing  in compliance with the IUSCC data quality  
control review process.  
17.2 Data and Safety Monitoring Plan  
This trial will comply with the current requirements of the Data and Safety Monitoring Plan 
(DSMP) of the IUSCC. The CTO  of the IUSCC will be the Coordinating Center for this phase [ADDRESS_1113017] 
and/or study nurse (or o ther members will be present at the Princip al Inve stigator’s discretion ).  
Monthly  meeting summaries should include review of data, the number of patients, significant 
toxicities as described in the protocol, and responses observed.  Summaries will be submitted  to 
DSM [EMAIL_15342]  and reviewed monthly  by [CONTACT_394268] . Monthly meeting summaries will include 
and document review of data and patient safety by [INVESTIGATOR_3086]:  the number of patients, significant 
toxicities as described in the protocol , responses observed, eligibility of patients enrolled at each 
site, serious adverse events (SAEs) or unanticipated problems (UPs) (both IUSCC and those 
reported from other institutions), dose adjustments, and protocol deviations.  Meeting minutes 
will be submitted and reviewed by [CONTACT_6802].  
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113018] to auditing and/or monitoring. Reports wil l be 
reviewed by [CONTACT_197582] (Reference Risk Table in fu ll DSMC 
Charter).  
 
 Early Study Closure  
At any time during the conduct of the trial, if it is the opi[INVESTIGATOR_85263] 
(or benefits) to the patient warrant early closure of the study, this recommendation should be 
made in writing to the Data Safety Monitoring Committee.  Alternatively, the DSMC may 
initiate suspension or early closure of the study based on its review.  
 
Reporting Guidelines  
The DSMC has streamlined the reporting process by [CONTACT_164953]®. This has 
allowed direct view of reports within the Clinical Trials  Management System ( CTMS); thus, 
discontinuing all paper reports. SAE reports are entered into OnCore® monthly and reviewed by 
[CONTACT_85281]/or coordinator monthly. Findings will be r eported to the full DSMC at the 
time of the studies DSMC review.  
 
Reporting Death   
Death will be captured in t he Case Report Form and reported  per local IRB reporting guidelines.  
 
Study Accrual Oversight  
Accrual data will be entered into the IU Simon Cancer Center OnCore® system. The Protocol 
Progress  Committee ( PPC) will review study accrual twice per year while the PPC coordinator 
will review accrual quarterly.  
 
Continuing Review    
All Continuing Reviews (CR) will be reviewed annually or as dictated by [CONTACT_98405].  Participating s ites will submit a copy of the CR with attachments to the IUSCC 
Multicenter Network Associate Administrator, or designee . 
 
Protocol Devi ations  
Protocol deviations will be entered into OnCore® and reviewed by [CONTACT_85281]/or 
coordinator. Findings will be reported to the full DSMC at the time of DSMC review .  
 
Unanticipated Problems  
Investigators are required to submit unanticipated problems to the DSMC (through OnCore®) 
concurrent with their submission of them to the IRB.  Prompt reporting of unanticipated 
problems  to the IRB is defined as within 5 days for on -site studies.  
 
Unanticipated problems  that will be reported promptly to the IRB include:  
 Major p rotocol deviation/violation  
 Change to the protocol taken without prior IRB review to eliminate apparent immediate 
hazard to a research subject (e.g. purposeful and for subject safety)  
 Complaint of a subject that indicates unexpec ted risks, or complaint that cannot be resolved 
by [CONTACT_806337] [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 38  Publication in the literature , safety monitoring report, interim result or other finding  that 
indicates an unexpected change to the risks or potential benefits of the research , in terms o f 
severity or frequency  
 Change in FDA labeling or withdrawal from marketing of a drug, device, or biologic used in 
a research study  
 Investigator - or sponsor -initiated suspension or hold  
 Serious or continuing n on-compliance  
 Adverse events  
 
18. REPORTING ADVERSE EVENTS  
18.1 Definitions of Adverse Events  
18.1.1 Adverse Event (AE)  
An adverse event  is defined as an unplanned, unwanted  medical occurrence ass ociated 
with the use of a drug in humans, whether or not considered drug related. An adverse 
event can be ANY  unfavorable and unintended sign (e.g. an abnormal laboratory 
finding), symptom, or disease temporarily associated with the use of a medicinal 
(investigational) product, whether or not considered related to the medicinal 
(investigational) product (attribution of ‘unrelated’, ‘unlikely’, ‘possible’, ‘probable’, or 
‘definite’).  An AE may also include a newly occurring event or a previous condition tha t 
has increased in severity or frequency since the administration of the investigational 
product. Adverse events will be graded according to the NCI Common Toxicity Criteria, 
Version 4.0. A copy of the current CTCAE version 4 is available at 
http://ctep.cancer.gov/reporting/ . 
18.1.2 Unexpected Adverse Event  
An adverse event not mentioned in the Investigator's Brochure or package insert or the 
specificity or severity of which is not consistent with the Inv estigator's brochure or 
package insert.  
18.1.3 Unanticipated Problem (UP)  
An unanticipated problem is any incident, experience, or outcome that meets all of the 
following criteria:  
1) unexpected (in terms of nature, severity, or frequency) given (a) the research  
procedures are described in the protocol -related documents, such as the IRB -
approved research protocol and informed consent document; and (b) the 
characteristics of the subject population being study;  
2) related or possibly related to participation in the re search; and  
3) suggests that the research places subjects or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) related to the 
research than was previously known or recognized.  
Only a small subset of adverse events  occurring in human subjects participating in 
research will meet these three criteria for an unanticipated problem. Furthermore, there 
are other types of incidents, experiences, and outcomes that occur during the conduct of 
human subjects research that rep resent unanticipated problems but are not considered 
adverse events. For example, some unanticipated problems involve social or economic 
harm instead of the physical or psychological harm associated with adverse events. In Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113019] subjects or others at increased risk of harm, but 
no harm occurs.  
18.1.4 Determining Attribution to the Investigational Agent(s)  
Attribution: An assessment of the relationship between the AE and the medical 
intervention. CTCAE does not define an A E as necessarily “caused by a therapeutic 
intervention” . AEs will be monitored until they are resolved or are clearly determined to 
be due to a subject’s stable or chronic condition or intercurrent illness.  
 
After naming and grading the event, the clinica l investigator must assign an attribution ; 
or the determination of whether an adverse event is related to a medical treatment or 
procedure. The categories of attribution are  described below :  
Relationship  Attribution  Description  
Unrelated to investigational 
agent/intervention  Unrelated  The AE is clearly NOT related  
Unlikely  The AE is doubtfully related  
Related to investigational 
agent/intervention  Possible  The AE may be related  
Probable  The AE is likely related  
Definite  The AE is clearly related  
18.1.5 Serious Adverse Event (SAE)  
A serious adverse event is any untoward medical occurrence resulting in one or more of 
the following:  
 Results in death  or ANY death occurring within [ADDRESS_1113020] dose of study 
drug (even if it is not felt to be drug related)  
 Is life -threatening (defined as an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event which hypothetically might 
have caused death if it were more severe)  
 Requires inpatient hospi[INVESTIGATOR_12331]: Hospi[INVESTIGATOR_85265]:  
 Hospi[INVESTIGATOR_806311]  
 Hospi[INVESTIGATOR_5187] a pre -existing condition 
unrelated to the study medication  
 Results in persistent or significant disability/incapacity  
 Is a congenital anomaly or birth defect  
 Is an important medical event (defined as a medical event(s) that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_313], based upon 
appropriate medical and scientific judgment, may jeopardize the patient or may 
require intervention ( e.g. medical, surgical) to prevent one of the other serious 
outcomes listed in the definition above).  Examples of such events include, but 
are not limited to, intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions not resulting in 
hospi[INVESTIGATOR_1916]; or the development of drug dependency or drug abuse.  
  Pregnancy  
Pregnancy of a patient or of the female partner of a male patient during the study 
or within [ADDRESS_1113021] dose of study drug should be reported via an SAE 
report.  Should p regnancy occur in a female participant during the treatment Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 40 period, study drug should be discontinued immediately.  Should a pregnancy 
occur in a female companion of a male participant during the treatment period, 
the male participant can continue treatmen t immediately . Any such pregnancy is 
to be followed until final outcome.   
18.2 Adverse Event (AE) Reporting  
Adverse events (AEs) will be recorded from the time of first study drug administration and for at 
least 30 days after treatment discontinuation, re gardless of whether or not the event(s) are 
considered related to trial medications.  All AEs considered related to trial medication will be 
followed until resolution, return to baseline, or deemed clinically insignificant,  even if this 
occurs post -trial.  
18.2.1  Reporting to the Data Safety Monitoring Committee (DSMC):  
Regardless of study sponsorship, the DSMC chair and/or coordinator will review all 
expedited SAE reports through OnCore®. Expedited reports are completed per IRB 
guidelines and may include t he IRB Prompt Reporting form, and/or non -compliance 
form. Submission of this information to the DSMC is additional to  any other protocol -
specified regulatory bodies ( e.g. FDA, pharmaceutical company) to be notified.  When 
follow -up information is received,  a follow -up report should also be created in OnCore®.  
The DSMC chair and/or coordinator will review expedited SAE reports monthly . 
 
18.2.2 Reporting to the IRB  
Each participating site will report adverse events and unanticipated problems to their IRB 
per local guidelines. Any event that requires expedited reporting to the local IRB will 
also be submitted to the IU Simon Cancer Center . 
 
Unanticipated problems involving risks to subjects or others will be reported promptly to 
the IRB if they:  
 caused har m;  
 were unexpected; AND  
 were related or possibly related to the research intervention . 
 
If the serious adverse event does not meet all three (3) criteria listed above, the event 
does not have to be promptly reported to the Indiana University  IRB.  However , it should 
be reported at the time of continuing review . 
 
Prompt reporting of unanticipated problems  to the IRB is defined as within [ADDRESS_1113022] Retention  
All documentation of adverse events and  records of  all IRB correspondence will be stored in 
accordance with all applicable federal guidelines.  
 
20. REFERENCES  
1. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010 Apr 
29;362(17):1605 -17. PubMed PMID: 20427809.  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 41 2. Neop tolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. 
Adjuvant 5 -fluorouracil and folinic acid vs observation for pancreatic cancer: composite 
data from the ESPAC -1 and -3(v1) trials. British journal of cancer. 2009 Jan 
27;100(2):246 -50. PubMed PMID: 19127260. Pubmed Central PMCID: 2625958.  
3. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant 
chemotherapy with gemcitabine and long -term outcomes among patients with resected 
pancreatic cancer: the CONKO -001 randomized trial. JAMA : the journal of the 
American Medical Association. [ADDRESS_1113023] 9;310(14):1473 -81. PubMed PMID: 24104372.  
4. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. 
Improvements in survival and clinical benef it with gemcitabine as first -line therapy for 
patients with advanced pancreas cancer: a randomized trial. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 1997 Jun;15(6):2403 -13. 
PubMed PMID: 9196156.  
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. 
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England 
journal of medicine. 2011 May 12;364(19):1817 -25. PubMed PMID: 21561347.  
6. Von Hoff DD, Ervin T, Arena FP, Ch iorean EG, Infante J, Moore M, et al. Increased 
survival in pancreatic cancer with nab -paclitaxel plus gemcitabine. The New England 
journal of medicine. [ADDRESS_1113024] 31;369(18):1691 -703. PubMed PMID: 24131140.  
7. Gillen S, Schuster T, Meyer Zum Buschenfelde C,  Friess H, Kleeff J. 
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta -
analysis of response and resection percentages. PLoS medicine. 2010 Apr;7(4):e1000267. 
PubMed PMID: 20422030. Pubmed Central PMCID: 2857873.  
8. White R R, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant 
chemoradiation for localized adenocarcinoma of the pancreas. Annals of surgical 
oncology. 2001 Dec;8(10):758 -65. PubMed PMID: 11776488.  
9. Evans DB, Rich TA, By[CONTACT_3238], Cleary KR, Con nelly JH, Levin B, et al. Preoperative 
chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
Archives of surgery. 1992 Nov;127(11):1335 -9. PubMed PMID: 1359851.  
10. Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M , et al. 
Histopathological response to preoperative chemoradiation for resectable pancreatic 
adenocarcinoma: the French Phase II FFCD 9704 -SFRO Trial. American journal of 
clinical oncology. 2008 Dec;31(6):545 -52. PubMed PMID: 19060585.  
11. Satoi S, Yanagim oto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, et al. Surgical 
results after preoperative chemoradiation therapy for patients with pancreatic cancer. 
Pancreas. 2009 Apr;38(3):282 -8. PubMed PMID: 19142173.  
12. Papalezova KT, Tyler DS, Blazer DG, 3rd, C lary BM, Czito BG, Hurwitz HI, et al. Does 
preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? 
Journal of surgical oncology. 2012 Jul 1;106(1):111 -8. PubMed PMID: 22311829.  
13. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pi[INVESTIGATOR_8190], et al. Preoperative 
gemcitabine -based chemoradiation for patients with resectable adenocarcinoma of the 
pancreatic head. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2008 Jul 20;26(21):34 96-502. PubMed PMID: 18640930.  
14. Turrini O, Ychou M, Moureau -Zabotto L, Rouanet P, Giovannini M, Moutardier V, et al. 
Neoadjuvant docetaxel -based chemoradiation for resectable adenocarcinoma of the 
pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic 
response. European journal of surgical oncology : the journal of the European Society of Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113025];36(10):987 -92. PubMed PMID: 20828979.  
15. Barbier L, Turrini O, Gregoire E, Viret F, Le Treut YP, Delpero JR. Pancreatic head 
resectable adenocarcinoma: preoperative chemoradiation improves local control but does 
not affect survival. HPB : the official journal of the International Hepato Pancreato 
Biliary Association. 2011 Jan;13(1):64 -9. PubMed PMID: 21159106. Pubmed Central 
PMCID: 3019544.  
16. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A 
randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: 
gemcitabine al one versus gemcitabine combined with cisplatin. Annals of surgical 
oncology. 2007 Jul;14(7):2088 -96. PubMed PMID: 17453298.  
17. Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified 
FOLFIRINOX regimen with improved safety and maintained ef ficacy in pancreatic 
adenocarcinoma. Pancreas. 2013 Nov;42(8):1311 -5. PubMed PMID: 24152956.  
18. Rafael Alvarez -Gallego AC, Jesus Rodriguez -Pascual, Yolanda Quijano, Emilio De 
Vicente, Lina García, Fernando López -Ríos, Carlos Plaza, Elena García -García, Ma ría 
Pia Morelli, Manuel Hidalgo. Antitumor activity of nab -paclitaxel and gemcitabine in 
resectable pancreatic cancer. J Clin Oncol 30, 2012 (suppl; abstr 4040). 2012.  
19. Shawn MacKenzie HZ, Laurence E. McCahill, Timothy D. Sielaff, Nathan Bahary, 
Thomas Edward Gribbin, John E. Seng, Joseph W. Leach, Jocelyn Harmon, Michael J. 
Demeure, Daniel D. Von Hoff, A Jim Moser, Ramesh K. Ramanathan. A pi[INVESTIGATOR_806312] -paclitaxel (Nab -P) and gemcitabine (G) as preoperative therapy 
for potential ly resectable pancreatic cancer (PC). J Clin Oncol 31, 2013 (suppl; abstr 
4038). 2013.  
20. Neelam Vijay Desai SH, Alison Ivey, Steven N. Hochwald, Carmen Joseph Allegra, Jose 
Gilberto Trevino, Long H. Dang, Kevin Behrns, Judith L. Lightsey, Robert Zlotecki , 
Chen Liu, Shailendra Chauhan, Maria Zajac -Kaye, Tania Zuluaga Toro, Wei Hou, 
Thomas J. George. Gemcitabine with nab -paclitaxel in neoadjuvant treatment of 
pancreatic adenocarcinoma: GAIN -1 study. J Clin Oncol 30, 2012 (suppl; abstr 
TPS4136). 2012.  
21. Lexi-Comp. Fluorouracil: Drug Information 2010 [cited 2010 Sept 29, 2010].  
22. Douglas B. Evans; Tyvin A. Rich; David R. By[CONTACT_26752]; Karen R. Cleary; John H. Connelly; 
Bernard Levin; Chusilp Charnsangavej; Claudia J. Fenoglio; Frederick C. Ames,   
Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the 
Pancreas  Arch Surg. 1992;127(11):1335 -1339.  
23. Ottery, Faith & Jager -Wittenaar, Harriët.  PG -SGA.  http://www.pt -global.org.  
24.  Chang VT, Xia Q, Kasimis B. The Functional Assessment o f Anorexia/Cachexia Therapy 
(FAACT) Appetite Scale in veteran cancer patients. J Support Oncol. [ADDRESS_1113026];3(5):377 -82. 
 
 
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October [ADDRESS_1113027] version of the Common Toxicity Criteria, copi[INVESTIGATOR_164926].  
 
An electronic copy is available on the CTEP web site , http://ctep.cancer.gov/reporting/ctc.html  
 
 
  Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 44 Appendix  II 
Performance Status Scales/Scores  
 
       ECOG or Zubrod                              Karnofsky                  Lansky     
 
Score        Activity               Score                Activity                      Score               Activity  
0 Fully active, able 
to carry on all pre -
disease 
performance 
without restriction.  100 
 
 
90 Normal, no complaints, no 
evidence of disease.  
 
Able to carry on normal 
activity; minor signs or 
symptoms of disease.  
 100 
 
 
90 Fully active, normal.  
 
 
Minor restrictions in  physically 
strenuous activity.  
1 Restricted in 
physically 
strenuous activity 
but ambulatory 
and able to carry 
out work of a light 
or sedentary 
nature, e.g. light 
housework, office 
work.  80 
 
 
 
 
70 Normal activity with effort; 
some signs or symptoms of 
disease.  
 
Cares for self, unable to 
carry on normal activity or 
do active work.  80 
 
 
 
 
70 Active, but tires more quickly.  
 
 
 
Both greater restriction of and 
less time spent in play activity.  
2 Ambulatory and 
capable of all 
selfcare but unable 
to carry out  any 
work activities.  
Up and about more 
than 50% of 
waking hours.   
 
[ADDRESS_1113028] of his/her 
needs.  
 
Requires considerable 
assistance and frequent 
medical care.   
 
60 
 
 
 
50 Up and around, but minimal 
active play; keeps busy with 
quieter activities.  
 
 
Gets dressed, but lies around 
much of the day; no active play; 
able to participate in all quiet 
play and activities.  
3 Capable of only 
limited selfcare, 
confined to bed or 
chair more than 
50% of waking 
hours.  40 
 
 
 
30 Disabled, requires special 
care and assistance.  
 
Severely disabled, 
hospi[INVESTIGATOR_374].  
Death not imminent.  40 
 
 
 
30 Mostly in bed; participates in 
quiet activities.  
 
In bed; needs assistance even 
for quiet play.  
4 Completely 
disabled.  Cannot 
carry on any 
selfcare. Totally 
confined to bed or 
chair.  20 
 
 
10 Very sick, hospi[INVESTIGATOR_373].  Death not 
imminent.  
Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  20 
 
 
10 
 Often sleepi[INVESTIGATOR_007]; play entirely 
limited to very passive 
activities.  
No play; does not get out of 
bed. 
 Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 45 Appendix III  
DSMC Check Sheet  
 
 
  
Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 46 Appendix IV  
Scored Patient -Generated Subjective Global Assessment (PG -SGA)  
Patient ID__________            Patient Initials___________                     Date_______________  
 
 
 
Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 47  
  
Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 48 Appendix V  
Functional Assessment of Anorexia/Cachexia Therapy (FAACT)  
Patient ID__________            Patient Initials__________ _                     Date_______________  
 
 
Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 49  
Protocol [PHONE_16817] IRB Approved for re-consenting only
IUCRO -0473  
Protocol Version Date:   
October 2 , 201 9  Page 50  
Protocol [PHONE_16817] IRB Approved for re-consenting only